<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32063853</article-id>
<article-id pub-id-type="pmc">7000454</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2019.01638</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Waddington</surname>
<given-names>John L.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhen</surname>
<given-names>Xuechu</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O’Tuathaigh</surname>
<given-names>Colm M. P.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/132725" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland</institution>, <addr-line>Dublin</addr-line>, <country>Ireland</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Jiangsu Key Laboratory of Translational Research &amp; Therapy for Neuro-Psychiatric Disorders and Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University</institution>, <addr-line>Suzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Medical Education Unit, School of Medicine, Brookfield Health Sciences Complex, University College Cork</institution>, <addr-line>Cork</addr-line>, <country>Ireland</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Adrian Preda, University of California, Irvine, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Kazutaka Ohi, Kanazawa Medical University, Japan; Francesco Papaleo, Italian Institute of Technology (IIT), Italy; Antonieta Lavin, Medical University of South Carolina, United States</p>
</fn>
<corresp id="fn001">*Correspondence: John L. Waddington, <email xlink:href="mailto:jwadding@rcsi.ie" xlink:type="simple">jwadding@rcsi.ie</email>
</corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>29</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>1638</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>12</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Waddington, Zhen and O’Tuathaigh</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Waddington, Zhen and O’Tuathaigh</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Alongside positive and negative symptomatology, deficits in working memory, attention, selective learning processes, and executive function have been widely documented in schizophrenia spectrum psychosis. These cognitive abnormalities are strongly associated with impairment across multiple function domains and are generally treatment-resistant. The DTNBP1 (dystrobrevin-binding protein-1) gene, encoding dysbindin, is considered a risk factor for schizophrenia and is associated with variation in cognitive function in both clinical and nonclinical samples. Downregulation of DTNBP1 expression in dorsolateral prefrontal cortex and hippocampal formation of patients with schizophrenia has been suggested to serve as a primary pathophysiological process. Described as a “hub,” dysbindin is an important regulatory protein that is linked with multiple complexes in the brain and is involved in a wide variety of functions implicated in neurodevelopment and neuroplasticity. The expression pattern of the various dysbindin isoforms (-1A, -1B, -1C) changes depending upon stage of brain development, tissue areas and subcellular localizations, and can involve interaction with different protein partners. We review evidence describing how sequence variation in DTNBP1 isoforms has been differentially associated with schizophrenia-associated symptoms. We discuss results linking these isoform proteins, and their interacting molecular partners, with cognitive dysfunction in schizophrenia, including evidence from drosophila through to genetic mouse models of dysbindin function. Finally, we discuss preclinical evidence investigating the antipsychotic potential of molecules that influence dysbindin expression and functionality. These studies, and other recent work that has extended this approach to other developmental regulators, may facilitate identification of novel molecular pathways leading to improved antipsychotic treatments.</p>
</abstract>
<kwd-group>
<kwd>cognitive deficits</kwd>
<kwd>developmental gene</kwd>
<kwd>schizophrenia</kwd>
<kwd>antipsychotic drug development</kwd>
<kwd>dysbindin-1</kwd>
</kwd-group>
<counts>
<fig-count count="0"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="139"></ref-count>
<page-count count="12"></page-count>
<word-count count="5801"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<sec id="s1_1">
<title>Schizophrenia, Cognitive Impairment, and Functional Disability</title>
<p>Schizophrenia is a complex psychiatric disorder that is the exemplar of a broader spectrum of psychotic illness in which interactive contributions from genetic and environmental factors play critical roles in etiology and pathobiology (<xref ref-type="bibr" rid="B87">Owen et al., 2016</xref>); hereafter, we use the term schizophrenia as shorthand for this spectrum of illness. In intimacy with positive, psychotic symptoms that define this spectrum, dysfunction in working memory, attention, processing speed, visual and verbal learning, reward-related learning, and prominent deficits in executive function have been extensively documented in schizophrenia (<xref ref-type="bibr" rid="B60">Kahn and Keefe, 2013</xref>). Impairment across these domains, in juxtaposition with negative symptoms, has long been accepted as core features of schizophrenia that contribute substantively to disability and are generally treatment refractory (<xref ref-type="bibr" rid="B49">Green et al., 2019</xref>).</p>
<p>Several authors have recommended inclusion of cognitive impairment in formal diagnostic criteria for this illness, as well as highlighting the need for research on developing new and more effective treatments to enhance cognitive abilities therein (<xref ref-type="bibr" rid="B60">Kahn and Keefe, 2013</xref>; <xref ref-type="bibr" rid="B99">Schaefer et al., 2013</xref>; <xref ref-type="bibr" rid="B79">Mark and Toulopoulou, 2016</xref>). Cognitive deficits associated with schizophrenia are observed in unaffected family members of individuals with the disorder (<xref ref-type="bibr" rid="B123">Toulopoulou et al., 2019</xref>) and the presence of schizophrenia-associated cognitive impairment in children can predict increased risk for the illness (<xref ref-type="bibr" rid="B82">Meier et al., 2014</xref>; <xref ref-type="bibr" rid="B1">Agnew-Blais et al., 2015</xref>).</p>
</sec>
<sec id="s1_2">
<title>Schizophrenia, Cognitive Impairment, and Genetics</title>
<p>Twin studies continue to affirm a primary role for genetic factors in the etiology of schizophrenia (<xref ref-type="bibr" rid="B55">Hilker et al., 2018</xref>), in association and interaction with environmental adversities (<xref ref-type="bibr" rid="B50">Guloksuz et al., 2019</xref>). However, despite considerable endeavour during the past 20 years, genomic studies of schizophrenia have arguably failed to provide the expected answers, or have highlighted the difficulties in elucidating a complex, heterogeneous, and polygenic genetic architecture. The existing literature indicates contributions from multiple common and occasional rare variants that may interact in conferring risk for schizophrenia (<xref ref-type="bibr" rid="B8">Bergen et al., 2019</xref>; <xref ref-type="bibr" rid="B132">Weinberger, 2019</xref>). A key challenge in this field involves the translation of advances in our understanding of the genetics of schizophrenia and the mechanistic basis of these associations into tangible improvements in patient-centred care and antipsychotic drug discovery.</p>
<p>In support of a common disease-common allele hypothesis, whereby much of risk for schizophrenia is conferred <italic>via</italic> the cumulative effect of multiple common alleles, a landmark genome wide association study of more than 36,000 cases and over 113,000 controls identified 108 loci for common risk variants that achieved genome-wide significance (<xref ref-type="bibr" rid="B101">Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014</xref>). These risk variants are involved in several known processes, including synaptic plasticity and within the major histocompatibility complex, but also in as-yet unknown functions. In the most recent analysis completed by the same consortium, which involved 30,000 additional subjects, the number of GWAS-significant loci was expanded to 246 (<xref ref-type="bibr" rid="B132">Weinberger, 2019</xref>).</p>
<p>Polygenic risk scores (PRS) represent an aggregate measure of genetic risk as they consider the additive effects of all significant variation across multiple genes and regulatory areas across the entire genome (<xref ref-type="bibr" rid="B59">Jones et al., 2016</xref>; <xref ref-type="bibr" rid="B133">Xavier et al., 2018</xref>; <xref ref-type="bibr" rid="B123">Toulopoulou et al., 2019</xref>). The PRS is calculated by summing all the alleles (weighted by their individual odds ratios) that have been associated with an illness in the latest GWAS data set for that illness. In the most recent study of the effect of schizophrenia risk alleles on cognition (<xref ref-type="bibr" rid="B96">Richards et al., 2019</xref>), schizophrenia PRS were associated more strongly with case-control cognitive differences as opposed to variation within cases.</p>
<p>Copy number variants (CNVs), both rare <italic>de novo</italic> and inherited, make only a minor contribution to population risk variation despite larger effect sizes (<xref ref-type="bibr" rid="B78">Manolio et al., 2009</xref>; <xref ref-type="bibr" rid="B75">Malhotra and Sebat, 2012</xref>; <xref ref-type="bibr" rid="B64">Kotlar et al., 2015</xref>; <xref ref-type="bibr" rid="B41">Genovese et al., 2016</xref>). In schizophrenia, these rare variants are found at loci containing genes implicated in synaptic function as well as neurodevelopmental processes linked with glutamatergic function pathways (<xref ref-type="bibr" rid="B61">Kirov et al., 2012</xref>; <xref ref-type="bibr" rid="B80">Marshall et al., 2017</xref>). <xref ref-type="bibr" rid="B41">Genovese et al. (2016)</xref> reported that genes implicated in synaptic function potentially explained more than 70% of the exome enrichment in damaging ultra-rare variants that contribute to schizophrenia. Some authors have proposed a merging of common allele and rare variant mechanisms, suggesting that individuals with schizophrenia having well-characterized pathogenic CNVs also associate with an excess burden of common risk alleles (<xref ref-type="bibr" rid="B122">Tansey et al., 2016</xref>; <xref ref-type="bibr" rid="B8">Bergen et al., 2019</xref>).</p>
<p>More recent hypotheses suggest that the complex genetic architecture of schizophrenia may be better explained in terms of an “omnigenic” framework. This hypothesis (<xref ref-type="bibr" rid="B14">Boyle et al., 2017</xref>) posits that for complex traits such as schizophrenia, GWAS may identify genes more central to a disease process. However, these “core” genes function in a cellular network that is associated with the vastly more numerous other “peripheral” genes that have less evident relationship to disease but are able to influence the function of “core” genes. Indeed, recent evidence suggests in schizophrenia a “core” gene set that appears to contribute to risk to a greater extent than an omnigenic background effect (<xref ref-type="bibr" rid="B95">Rammos et al., 2019</xref>).</p>
</sec>
</sec>
<sec id="s2">
<title>Schizophrenia, Cognitive Impairment, and Variation in DTNBP1</title>
<p>Dysbindin-1 is a coiled-coil-containing protein encoded by DTNBP1 (Dystrobrevin Binding Protein 1, 6p22.3), a gene that has been linked with cognitive and anatomical endophenotypes in both patients with neuropsychiatric disorders as well as nonclinical samples (<xref ref-type="bibr" rid="B4">Ayalew et al., 2012</xref>; <xref ref-type="bibr" rid="B127">Wang et al., 2017</xref>; <xref ref-type="bibr" rid="B98">Savage et al., 2018</xref>). An initial report of genetic linkage to schizophrenia on chromosome 6p24-22 (<xref ref-type="bibr" rid="B108">Straub et al., 1995</xref>) was followed by multiple individual replications and confirmatory meta-analyses of DTNBP1 (<xref ref-type="bibr" rid="B2">Allen et al., 2008</xref>; <xref ref-type="bibr" rid="B4">Ayalew et al., 2012</xref>; <xref ref-type="bibr" rid="B127">Wang et al., 2017</xref>); any concern that such findings have not been prominent in GWAS studies to date (<xref ref-type="bibr" rid="B38">Farrell et al., 2015</xref>) must be juxtaposed with increasing recognition that GWAS cannot in itself be considered definitive on such issues (<xref ref-type="bibr" rid="B118">Tam et al., 2019</xref>; see also <italic>Schizophrenia, Cognitive Impairment, and Genetics</italic> above), and that the GWAS focus on diagnosis and symptom severity scores is likely to lead to neglect for genes specifically linked with cognitive dysfunction in schizophrenia. Additionally, the expression of dysbindin-1 and its isoforms is disrupted in brain tissue from schizophrenia patients (see <italic>Schizophrenia Pathobiology and Dysbindin Isoforms</italic> below). Importantly for issues to be considered further below, variations in DTNBP1 associated with schizophrenia (SNPs and haplotypes) are located in intron or promoter regions and almost all are located in the N-terminus of the gene (<xref ref-type="bibr" rid="B51">Guo et al., 2008</xref>).</p>
<p>Several studies have investigated the role of this gene in cognitive deficits of schizophrenia. For example, DTNBP1 haplotypes are associated with greater decline in IQ (<xref ref-type="bibr" rid="B20">Burdick et al., 2007</xref>) and impairment in spatial working memory (<xref ref-type="bibr" rid="B33">Donohoe et al., 2007</xref>; <xref ref-type="bibr" rid="B34">Donohoe et al., 2008</xref>; <xref ref-type="bibr" rid="B35">Donohoe et al., 2010</xref>) and attentional/vigilance (<xref ref-type="bibr" rid="B5">Baek et al., 2012</xref>), verbal and visual working memory and speed of processing (<xref ref-type="bibr" rid="B124">Varela-Gomez et al., 2015</xref>), as well as executive function (<xref ref-type="bibr" rid="B100">Scheggia et al., 2018</xref>). Such findings have been less evident on subdividing schizophrenia patients into cognitive-deficit and cognitive-sparing groups (<xref ref-type="bibr" rid="B91">Peters et al., 2008</xref>). Other studies have also failed to report a relationship between DTNBP1 variants and general tests of cognitive ability in patients with schizophrenia and first-degree relatives compared to controls (<xref ref-type="bibr" rid="B109">Strohmaier et al., 2010</xref>; <xref ref-type="bibr" rid="B26">Chow et al., 2018</xref>). Additionally, while some authors have shown that DTNBP1 variation in healthy controls and patients is associated with performance across a diverse range of cognitive tests (e.g. <xref ref-type="bibr" rid="B19">Burdick et al., 2006</xref>), a meta-analysis of 11 articles examining the relationship between dysbindin and general cognitive ability revealed only a modest relationship (<xref ref-type="bibr" rid="B138">Zhang et al., 2010</xref>). These results support involvement of the DTNBP1 gene in selective domains of cognition rather than non-specific cognitive ability (<xref ref-type="bibr" rid="B74">Luciano et al., 2009</xref>). Despite preliminary evidence to suggest dysbindin involvement in cognitive function in patients with brain tumours (<xref ref-type="bibr" rid="B27">Correa et al., 2016</xref>), there is a paucity of studies examining the role of dysbindin in other neurological and neuropsychiatric disorders where symptoms include cognitive dysfunction.</p>
</sec>
<sec id="s3">
<title>Schizophrenia Pathobiology and Dysbindin Isoforms</title>
<p>Dysbindin expression levels vary across neuronal populations throughout the brain and are particularly abundant in the dentate gyrus of the hippocampal formation (<xref ref-type="bibr" rid="B114">Talbot et al., 2004</xref>; <xref ref-type="bibr" rid="B115">Talbot et al., 2006</xref>), with dysbindin localization in the CNS occurring in both neurons and, at comparable levels, in glia (<xref ref-type="bibr" rid="B43">Ghiani et al., 2009</xref>; <xref ref-type="bibr" rid="B102">Shao et al., 2011</xref>). DTNBP1 encodes for three major splice isoforms of dysbindin-1: 1A, 1B, and 1C. Dysbindin-1A is most highly concentrated in postsynaptic density fractions and dysbindin-1B is most abundant in synaptic vesicle fractions; similar to dysbindin-1A, dysbindin-1C is most highly concentrated in postsynaptic density fractions; nuclear localization has also been reported for dysbindin-1A and -1B (<xref ref-type="bibr" rid="B88">Oyama et al., 2009</xref>; <xref ref-type="bibr" rid="B116">Talbot et al., 2011</xref>).</p>
<p>Sequence variation might be a mechanism by which the function of DTNBP1 differs between schizophrenia cases and controls. In this scenario, instead of a simple incorrectly encoded protein, the amount of DTNBP1 expression may be affected. Indeed, it has been shown that variations in DTNBP1 affect its expression in the human brain (<xref ref-type="bibr" rid="B16">Bray et al., 2003</xref>; <xref ref-type="bibr" rid="B17">Bray et al., 2005</xref>; <xref ref-type="bibr" rid="B18">Bray et al., 2008</xref>).</p>
<p>The hippocampal formation plays a fundamental role in working and episodic memory, highlighting the possible role of dysbindin in cognitive processes that are believed to be critical to schizophrenia (<xref ref-type="bibr" rid="B119">Tamminga et al., 2010</xref>). <xref ref-type="bibr" rid="B114">Talbot et al. (2004)</xref> reported that schizophrenia patients show reduction of dysbindin-1 protein in the principal neurons of CA2 and CA3 and especially in the dentate gyrus of the hippocampal formation. A subsequent study from the same group reported that dysbindin proteins in the dentate gyrus are essentially present postsynaptically (<xref ref-type="bibr" rid="B115">Talbot et al., 2006</xref>). <xref ref-type="bibr" rid="B116">Talbot et al. (2011)</xref> then reported that in schizophrenia patients levels of dysbindin-1B and -1C, but not -1A, are decreased in the hippocampal formation, while levels of dysbindin-1A, but not -1B or -1C, are decreased in the superior temporal gyrus. Furthermore, transcripts encoding dysbindin-1B are upregulated in peripheral blood leukocytes of patients with schizophrenia relative to controls, with an intronic DTNBP1 variant associated with schizophrenia affecting splicing and leading to specific over-expression of dysbindin-1B (<xref ref-type="bibr" rid="B134">Xu et al., 2015</xref>).</p>
<p>Similarly to the hippocampal formation, the dorsolateral prefrontal cortex (DLPFC) is crucially involved in working and episodic memory, highlighting a further possible contribution of dysbindin to cognitive deficits encountered in schizophrenia (<xref ref-type="bibr" rid="B71">Lewis et al., 2008</xref>). <xref ref-type="bibr" rid="B129">Weickert et al. (2004)</xref> reported varying levels of DTNBP1 mRNA within the DLPFC, with higher expression found in layers IV and V; in DLPFC of schizophrenia patients decreases in DTNBP1 mRNA were reported in layers II, III, V and VI, but not in layers I and IV. Subsequently, decreases in DTNBP1 mRNA were reported in the hippocampal formation (<xref ref-type="bibr" rid="B130">Weickert et al., 2008</xref>). However, a subsequent study from the same team could not wholly confirm these findings (<xref ref-type="bibr" rid="B40">Fung et al., 2011</xref>). <xref ref-type="bibr" rid="B121">Tang et al. (2009)</xref> reported reductions in dysbindin-1C, but not in -1A or -1B, in DLPFC in the absence of changes in mRNA levels of the three isoforms. It should be noted that laminar-specific alterations in dysbindin mRNA and proteins may have escaped detection with the homogenate-based approach used in both studies (<xref ref-type="bibr" rid="B121">Tang et al., 2009</xref>; <xref ref-type="bibr" rid="B40">Fung et al., 2011</xref>). More recently, dysbindin-1B, but not -1A, protein levels were found to be higher in the DLPFC in schizophrenia (<xref ref-type="bibr" rid="B63">Konopaske et al., 2018</xref>).</p>
</sec>
<sec id="s4">
<title>Schizophrenia, Neurodevelopment, Neuroplasticity, and Dysbindin</title>
<p>A wealth of epidemiological, clinical, and biological evidence now indicates that the origins of schizophrenia are to be found primarily in the early phases of fetal brain development: during this period a variety of factors, mainly genetic but also including environmental adversities, interact to disrupt brain morphogenesis (<xref ref-type="bibr" rid="B126">Waddington et al., 2012</xref>; <xref ref-type="bibr" rid="B12">Birnbaum and Weinberger, 2017</xref>); thereafter, endogenous and exogenous factors and processes can act to further “sculpt” brain development and maturation as a substrate from which the diagnostic symptoms and disabilities of clinical psychosis emerge, most typically during early adulthood (<xref ref-type="bibr" rid="B126">Waddington et al., 2012</xref>; <xref ref-type="bibr" rid="B131">Weinberger, 2017</xref>).</p>
<p>Regulation of brain development involves a multitude of genetic processes and associated proteins that act and interact sequentially to determine “normal” adult cerebral structure and function. Among these, dysbindin is one important regulator that is linked with multiple complexes in the brain and numerous diverse functions implicated in neurodevelopment and neuroplasticity. However, while the different dysbindin isoform proteins might interact with different partners, the majority of studies do not provide sufficient information to confirm or refute isoform-specific processes.</p>
<sec id="s4_1">
<title>Promotion of Cell Growth, Proliferation, and Antiapoptotic Effects</title>
<p>Dysbindin promotes activation of Akt (<xref ref-type="bibr" rid="B85">Numakawa et al., 2004</xref>), which mediates growth and proliferation of cells (<xref ref-type="bibr" rid="B77">Manning and Cantley, 2007</xref>). Akt has itself been proposed as a risk gene for schizophrenia and a target for antipsychotic drug development (<xref ref-type="bibr" rid="B139">Zheng et al., 2012</xref>; <xref ref-type="bibr" rid="B36">Enriquez-Barreto and Morales, 2016</xref>). Studies have reported that dysbindin is present in neurites and in axonal growth cones and that down regulation of dysbindin results in aberrant organisation of the actin cytoskeleton at the tips of neurites of differentiating cells, with shortening of such neurites (<xref ref-type="bibr" rid="B65">Kubota et al., 2009</xref>; <xref ref-type="bibr" rid="B120">Taneichi-Kuroda et al., 2009</xref>).</p>
</sec>
<sec id="s4_2">
<title>BLOC-1 and Endosomal Trafficking</title>
<p>Dysbindin is a stable component of the multi-subunit complex BLOC-1 (biogenesis of lysosome-related organelles complex-1; <xref ref-type="bibr" rid="B30">Dell’Angelica, 2004</xref>; <xref ref-type="bibr" rid="B73">Li et al., 2004</xref>; <xref ref-type="bibr" rid="B68">Lee et al., 2012</xref>). Among the subunits of BLOC-1, dysbindin interacts directly with pallidin, MUTED, and snapin (<xref ref-type="bibr" rid="B72">Li et al., 2003</xref>; <xref ref-type="bibr" rid="B107">Starcevic and Dell’Angelica, 2004</xref>). Mice containing constitutive deletion of the pallidin gene show performance deficits in two different measures of recognition memory: the novel object recognition task and a measure of social novelty recognition (<xref ref-type="bibr" rid="B106">Spiegel et al., 2015</xref>).</p>
<p>Studies have also reported an association between markers at MUTED and schizophrenia (<xref ref-type="bibr" rid="B111">Straub et al., 2005</xref>; but see also <xref ref-type="bibr" rid="B42">Gerrish et al., 2009</xref>). Moreover, both dysbindin and MUTED siRNA increased cell surface dopamine (DA) D2 receptors (D2R) and blocked DA-induced D2R internalization in human and rat cells. In contrast, decreased dysbindin altered neither D1 receptors (D1R) levels nor their basal expression or DA-induced internalisation (<xref ref-type="bibr" rid="B57">Iizuka et al., 2007</xref>). Such an increase in D2R signalling could contribute to the imbalance in DAergic neurotransmission characteristic of schizophrenia, i.e., hyperfunction through D2R and attenuation of such hyperfunction by current D2R antagonist antipsychotics (<xref ref-type="bibr" rid="B81">McCutcheon et al., 2019</xref>).</p>
<p>A recent review has comprehensively addressed the relationship and interactions between BLOC-1 genes/proteins and cognitive phenotypes observed in neurodevelopmental disorders (<xref ref-type="bibr" rid="B54">Hartwig et al., 2018</xref>). The predominant theme is that BLOC-1 subunits in brain areas linked to cognitive functions are part of a more complex set of molecular interactions, including proteins implicated in schizophrenia such as disrupted-in-schizophrenia-1 and SNARE (<xref ref-type="bibr" rid="B117">Talbot, 2009</xref>; <xref ref-type="bibr" rid="B54">Hartwig et al., 2018</xref>).</p>
</sec>
<sec id="s4_3">
<title>Dysbindin and Dystrophin-Associated Protein Complex</title>
<p>Dysbindin binds to the dystrobrevins, which are components of the dystrophin-associated protein complex (DPC) (<xref ref-type="bibr" rid="B7">Benson et al., 2001</xref>; but see also <xref ref-type="bibr" rid="B84">Nazarian et al., 2006</xref>). In the brain, several DPC-like complexes have been implicated in cognitive impairment commonly found in patients with Duchenne muscular dystrophy (DMD) (<xref ref-type="bibr" rid="B13">Blake and Kröger, 2000</xref>). Indeed, DPC is necessary for maturation and function of a subset of inhibitory synapses (<xref ref-type="bibr" rid="B48">Grady et al., 2006</xref>). Lack of dystrophin in the mdx mouse model of DMD produces an altered distribution of dysbindin in the brain, suggesting a role for dysbindin-1 in the cognitive impairment observed in DMD patients (<xref ref-type="bibr" rid="B104">Sillitoe et al., 2003</xref>).</p>
</sec>
</sec>
<sec id="s5">
<title>Nonisoform- and Isoform-Specific Genetic Mutation Models for Dysbindin-1 Function</title>
<sec id="s5_1">
<title>Drosophila Mutants</title>
<p>One dysbindin protein has been demonstrated in drosophila, known as CG6865-PA. While the amino acid sequence of its coiled-coil domain is closely related to that of all known orthologs of dysbindin, neither its N-terminal nor its C-terminal region is closely related to corresponding regions in any vertebrate dysbindin ortholog. CG6865-PA shares 28% amino acid identity with human dysbindin-1A (<xref ref-type="bibr" rid="B52">Guo et al., 2009</xref>). Drosophila dysbindin mutants demonstrate impaired neurotransmission, disrupted synaptic homeostasis, presynaptic and postsynaptic morphological alterations, and disruption in short term memory (<xref ref-type="bibr" rid="B32">Dickman and Davis, 2009</xref>; <xref ref-type="bibr" rid="B24">Cheli et al., 2010</xref>; <xref ref-type="bibr" rid="B102">Shao et al., 2011</xref>; <xref ref-type="bibr" rid="B45">Gokhale et al., 2015</xref>; <xref ref-type="bibr" rid="B83">Mullin et al., 2015</xref>; <xref ref-type="bibr" rid="B46">Gokhale et al., 2016</xref>).</p>
<p>
<xref ref-type="bibr" rid="B102">Shao et al. (2011)</xref> reported that neuronal disruption of dysbindin function in drosophila was associated with hypoglutamatergic transmission and deficits in working memory, while disruption of dysbindin function in glial cells was associated with hyperdopaminergia and locomotor hyperactivity; this latter effects was mediated <italic>via</italic> a reduction in the protein Ebony, a glia-specific beta-alanyl biogenic amine synthetase involved in metabolic degradation of biogenic amines in the nervous system. This study reveals distinct functions of dysbindin in neurons and glial cells and highlights the potential of new therapeutics for schizophrenia that target glial cells (<xref ref-type="bibr" rid="B9">Bernstein et al., 2015</xref>). As reduction of dysbindin in drosophila impacts on short-term memory, dysbindin-dependent pathways may shed further light on the mechanisms of cognitive dysfunction in schizophrenia (<xref ref-type="bibr" rid="B66">Larimore et al., 2014</xref>).</p>
</sec>
<sec id="s5_2">
<title>Mutant Mouse Models</title>
<p>Genetic mouse models enable etiologically related investigation of the pathophysiology of schizophrenia, providing means to advance target discovery to improve treatment for psychotic illness (<xref ref-type="bibr" rid="B86">O’Tuathaigh and Waddington, 2015</xref>). The development of new and effective drug therapies generally requires analysis of the intact brain in valid preclinical models, most commonly involving rodents (<xref ref-type="bibr" rid="B29">Dawson et al., 2015</xref>). Therefore, integrated research strategies for the delineation of animal models, based on characterization of cognitive deficits and underlying mechanisms, have considerable translational potential (<xref ref-type="bibr" rid="B31">Diamantopoulou and Gogos, 2019</xref>). In particular, based on the role of working memory in supporting a variety of cognitive abilities and its association with deficits in social and occupational functioning in schizophrenia, characterization of these processes in any mutant model is fundamental to understanding the relevance of the experimental model to cognitive dysfunction in this disorder.</p>
<p>While dysbindin-1A is highly conserved among vertebrates, there is no ortholog of human dysbindin-1B in mice; dysbindin-1C is a 270 amino acid protein in humans and a 271 amino acid protein in mice (<xref ref-type="bibr" rid="B117">Talbot, 2009</xref>). A spontaneous deletion mutation in DTNBP1 occurred in the DBA/2J strain, leading to complete absence of dysbindin-1A and 1C proteins in homozygous mice and reduced expression levels in heterozygous mice; the sandy (sdy) coat colour of homozygous mutants gives the strain its name (<xref ref-type="bibr" rid="B112">Swank et al., 1991</xref>). While the earliest studies were carried out in mice with the original DBA/2J background (sdy/DBA), the mutation has been transferred subsequently onto a C57BL/6J background (sdy/B6). DBA/2J mice are homozygous for at least six mutations, of which four are associated with neural impairments (<xref ref-type="bibr" rid="B28">Cox et al., 2009</xref>; <xref ref-type="bibr" rid="B117">Talbot, 2009</xref>). These appear to account for a number of auditory and visual deficits, when compared with C57BL/6 mice.</p>
</sec>
<sec id="s5_3">
<title>Sandy Mice on a DBA/2J Background</title>
<p>Studies indicated abnormalities related to cognitive impairment (disturbance of long-delay recognition memory during an object recognition test) in homozygous sdy/DBA mice without abnormalities related to basal activity levels or anxiety (<xref ref-type="bibr" rid="B39">Feng et al., 2008</xref>). These authors also confirmed a previous finding of direct interaction with and decrease in the steady-state level of snapin (a SNAP-25 binding protein), suggesting an upstream regulatory role of dysbindin on neurotransmitter release <italic>via</italic> snapin. <xref ref-type="bibr" rid="B113">Takao et al. (2008)</xref> also reported cognitive deficits, including impairment in long-term memory retention (Barnes maze test) and in working memory (T-maze, forced alternation task). <xref ref-type="bibr" rid="B10">Bhardwaj et al. (2009)</xref> also demonstrated deficits in short-term memory (object recognition memory test) and stronger dependent memory for fearful events in sdy/DBA mice. In a subsequent study such mutants showed impaired recognition memory in the novel object recognition and social recognition paradigms (<xref ref-type="bibr" rid="B106">Spiegel et al., 2015</xref>).</p>
<p>
<xref ref-type="bibr" rid="B62">Kobayashi et al. (2011)</xref> demonstrated hypersensitivity to both serotonergic and DAergic modulation of DG-to-CA3 signal transmission in 4-month-old to 6-month-old male homozygous sdy/DBA mice. These authors also reported decreased expression of D1R mRNA in the hippocampus that could contribute to changes in synaptic modulation. <xref ref-type="bibr" rid="B58">Jentsch et al. (2009)</xref> reported impaired glutamatergic transmission through potentially both presynaptic and postsynaptic mechanisms in the prefrontal cortex (PFC) of heterozygous and homozygous sdy/DBA mice. While dysbindin deletion appears to decrease glutamate release at the axon terminal, it may also result in an increase in excitability that might be due to reduction in neuronal dendritic branching and/or transmitter release in GABAergic interneurons. This study also reported homozygous sdy/DBA mice to show impairment in a spatial working memory task (delayed nonmatch-to-position test), with heterozygous mutants showing an intermediate level of performance. Collectively, these results suggest that dysbindin dysregulation might contribute to the cognitive symptoms of schizophrenia by decreasing glutamatergic transmission, at least in the prefrontal cortex.</p>
</sec>
<sec id="s5_4">
<title>Sandy Mice on a C57BL/6J Background</title>
<p>Studies involving the sandy mouse on a C57BL6 background also show cognitive deficits. <xref ref-type="bibr" rid="B28">Cox et al. (2009)</xref> first reported impairment in spatial memory and/or initial learning and acquisition (Morris water maze) in sdy/B6 mice. <xref ref-type="bibr" rid="B21">Carlson et al. (2011)</xref> reported reductions in sdy/B6 mice of auditory-evoked response adaptation, prepulse inhibition, and evoked γ-activity, which is most frequently linked with disrupted inhibition and reduction in parvalbumin (PV)-positive interneuron activity. Indeed, subsequent analyses revealed reduction of fast-spiking GABAergic inhibition and fewer PV cells in the hippocampus of sdy/B6 mice.</p>
<p>As previously shown in sdy/DBA mice (<xref ref-type="bibr" rid="B58">Jentsch et al., 2009</xref>), homozygous sdy/B6 mice showed a decrease in working memory performance (delayed nonmatch-to-position test) compared to wildtypes; these results correlated with degree of expression of the NR1 subunit of the NMDA receptor. Other studies have shown an altered GluN2B-GluN2A switch in the hippocampus and cortex of dysbindin mutant mice (<xref ref-type="bibr" rid="B105">Sinclair et al., 2016</xref>). Genetic loss of dysbindin-1 expression has also been shown to impact on NMDA receptor-dependent synaptic plasticity in the hippocampus in both sdy/DBA and sdy/B6 mice (<xref ref-type="bibr" rid="B44">Glen et al., 2014</xref>). Another study demonstrated that loss of dysbindin-1 leads to reduced mGluR1 signalling in the hippocampus, which is associated with altered hippocampal synaptic plasticity in sdy/B6 mice (<xref ref-type="bibr" rid="B11">Bhardwaj et al., 2015</xref>). Overall, these results suggest a role for dysbindin in the regulation of NMDA and cognition that might be associated with cognitive deficits in schizophrenia.</p>
<p>
<xref ref-type="bibr" rid="B89">Papaleo et al. (2012)</xref> reported differences in reference memory (T-maze) or a habituation/dishabituation task (olfactory discrimination test) in sdy/B6 mice, which demonstrated more rapid acquisition of a working memory task (T-maze) and overall worse performance on the same test under more demanding (proactive interference) or more stressful (transfer in a new cage) conditions relative to controls. Other data from the same group suggested that interval timing deficits may be a crucial component of abnormal cognition in sdy/B6 mice and that these deficits might be improved with increased training and experience (<xref ref-type="bibr" rid="B22">Carr et al., 2012</xref>).</p>
<p>Subsequent experiments were conducted to evaluate D2R modulation of these behavioral effects (<xref ref-type="bibr" rid="B89">Papaleo et al., 2012</xref>). While chronic D2R agonist administration did not affect acquisition in the working memory test, under more demanding conditions this treatment impaired working memory performance in a manner comparable to that observed in sdy/B6 mice. These authors also reported enhanced excitability and excitatory inputs to pyramidal neurons in medial-PFC (mPFC) layer II/III (the layers principally involved in intracortical projections), as well as decreased excitatory inputs to fast-spiking GABAergic neurons (<xref ref-type="bibr" rid="B89">Papaleo et al., 2012</xref>). DAergic modulation of excitatory synaptic transmission in layer II/III pyramidal neurons involves CaM-kinase-II (CaMKII)-dependent mechanisms that have been implicated in learning and memory processes (<xref ref-type="bibr" rid="B47">Gonzalez-Islas and Hablitz, 2003</xref>). While sdy/B6 mutants displayed lower CaMKII and CaMKKβ protein levels in mPFC, control mice chronically treated with a D2R agonist showed the same specific reductions (with no change in CaMKIV and CaMKKα levels; <xref ref-type="bibr" rid="B89">Papaleo et al., 2012</xref>). Overall, these results suggest that some effects of dysbindin on cognition, associated with changes in cortical activity and CaMK components of the mPFC, are induced <italic>via</italic> upregulation of D2R. Consistent with a dysbindin-associated increase in D2 receptors, dysbindin deficiency was associated with an antipsychotic-dependent increase in the ratio between the D2Short (D2S) and D2Long (D2L) isoforms in the PFC of mice, which is associated with potentiation of cortical presynaptic D2R signalling (<xref ref-type="bibr" rid="B100">Scheggia et al., 2018</xref>).</p>
<p>It has been proposed that DA signalling and PFC-dependent cognition follow an inverted U-shaped relationship, by which both inadequate or excessive DAergic signalling has a disruptive effect on cognitive performance that reflects an imbalance in dopamine D1/D2R activation (<xref ref-type="bibr" rid="B125">Vijayraghavan et al., 2007</xref>). Consistent with this hypothesis, <xref ref-type="bibr" rid="B90">Papaleo et al. (2014)</xref> investigated the effects on working memory performance of simultaneous disruption of dysbindin and the gene encoding the COMT enzyme, which plays a central role in the degradation of DA in PFC. They showed that while disruption of either dysbindin or COMT alone produced an improvement in working memory performance in the discrete paired-trial variable-delay T-maze task, mice with disruption of both genes demonstrated impaired working memory performance. These authors demonstrated a similar epistatic interaction on working memory performance and accompanying activation of PFC in humans. Based on the literature, the behavioral effects of this genetic interaction in both human and murine working memory paradigms reflect the effects of both genes on D1/D2R signalling in PFC. The same authors recently reported, in both mice and patients with schizophrenia, an interaction between functional variation in both dysbindin and D3R genes and working memory and executive function performance (<xref ref-type="bibr" rid="B69">Leggio et al., 2019</xref>). Specifically, simultaneous reduction of D3R and dysbindin function was associated with improved performance in tasks accessing these cognitive domains. It was shown that this epistatic interaction was associated with a shift in the balance between D2R and D3R receptor expression in the PFC, leading to an increase in D2R signalling in that brain region.</p>
</sec>
<sec id="s5_5">
<title>Dysbindin-1A Mutant Mice</title>
<p>We have recently described the generation of a genetic mouse model with isoform-specific deletion of dysbindin-1A protein (<xref ref-type="bibr" rid="B92">Petit et al., 2017</xref>). Initial phenotypic characterization showed sexually dimorphic phenotypes, with female knockouts (KO) being more reactive to stressful situations and male KO showing increased exploration during initial exposure to a novel environment that may be related to some disruption in habituation and dysregulation of hippocampus-dependent working memory function. No effect of genotype was observed during acquisition or during performance in long-term (olfactory) memory or either a conventional spatial working memory task (spontaneous alternation) or a low-interference delay-dependent working memory task; however, in a high-interference task variant, male KO mutants showed impairment in vulnerability to interference (<xref ref-type="bibr" rid="B92">Petit et al., 2017</xref>).</p>
</sec>
<sec id="s5_6">
<title>Dysbindin-1B Mutant Mice</title>
<p>Another recent study, which involved a transgenic mouse model expressing the human dysbindin-1B isoform, documented the presence of middle- and late-stage apoptosis in the hippocampus of dysbindin-1B mutants; in a T-maze alternation task, these mutants also showed deficits in working memory (<xref ref-type="bibr" rid="B135">Yang and Xu, 2017</xref>). Dysbindin-1B expression was also shown to impair spatial learning in the Morris water maze (<xref ref-type="bibr" rid="B136">Yang et al., 2016</xref>).</p>
</sec>
<sec id="s5_7">
<title>Dysbindin Gain-of-Function Mutant Mice</title>
<p>A further study described the behavioral phenotype of a gain-of-function dysbindin mutant (<xref ref-type="bibr" rid="B103">Shintani et al., 2014</xref>). Specifically, these authors generated a transgenic model that expressed the human dysbindin-1A isoform. Such mutants displayed unaltered sensory or motor behavior and no changes in anxiety, sensorimotor gating, or exploratory behavior; they evidenced heightened locomotor responsivity to methamphetamine and upregulation and downregulation of several genes in PFC, including decreases in Arc and Egr2 expression.</p>
</sec>
<sec id="s5_8">
<title>Spp Dysbindin Mutant Mice</title>
<p>Most recently, behavioral and cognitive phenotypes have been investigated in mice containing a single point mutation in the salt and pepper (spp) allele of DTNBP1 (<xref ref-type="bibr" rid="B23">Chang et al., 2018</xref>). While spp mutants did not exhibit any deficits in working memory (T-maze alternation task), some deficits in aspects of recognition memory performance were observed. These mice also demonstrated a reduction in the schizophrenia-associated SNAP-25 protein in PFC. No data are available regarding relative isoform expression in the brains of spp mutants.</p>
</sec>
<sec id="s5_9">
<title>Dysbindin Mutation × Exposure to Environmental Risk Factors</title>
<p>Emphasis on genetic risk factors for schizophrenia should be tempered by evidence from investigations in twins (<xref ref-type="bibr" rid="B55">Hilker et al., 2018</xref>) and epidemiological studies indicating a role for environmental factors that may act both independently and <italic>via</italic> gene-environment interactions (<xref ref-type="bibr" rid="B50">Guloksuz et al., 2019</xref>). Therefore, animal models of neuropsychiatric disorders can and should investigate experimental induction of/exposure to nongenetic risk factors, including psychosocial stress and biological insults. Though there is some debate around common pathological mechanisms underlying the impact of such manipulations on schizophrenia-related phenotypes (<xref ref-type="bibr" rid="B15">Bradshaw and Korth, 2019</xref>), a combination of dysbindin gene mutation and postnatal exposure to Poly I:C (a model of immune activation in relation to schizophrenia) has been investigated. In sdy/B6 mice, exposure to Poly I:C resulted in deficits in prepulse inhibition and recognition memory, together with findings contrary to expectations, such as reduced locomotion; sdy/B6 mice treated with Poly I:C also displayed attenuated contextual and cue-dependent fear conditioning memory (<xref ref-type="bibr" rid="B3">Al-Shammari et al., 2018</xref>).</p>
</sec>
</sec>
<sec id="s6">
<title>Dysbindin-1 and Putative Treatment Strategies for Cognitive Dysfunction in Schizophrenia</title>
<p>Consistent with the proposed role for the D2R in the PFC in mediating the putative effects of dysbindin variation on higher order cognitive processes (<xref ref-type="bibr" rid="B89">Papaleo et al., 2012</xref>; <xref ref-type="bibr" rid="B100">Scheggia et al., 2018</xref>; <xref ref-type="bibr" rid="B69">Leggio et al., 2019</xref>), a series of elegant translational studies have shown that patients and mice with genetic variation associated with decreased dysbindin-1 expression demonstrate improved responsivity to the effects of antipsychotic medication on executive function (<xref ref-type="bibr" rid="B100">Scheggia et al., 2018</xref>). Mechanistic interrogation of this interaction revealed that the cognitive response to antipsychotics was mediated by enhanced presynaptic D2R in PFC (<xref ref-type="bibr" rid="B100">Scheggia et al., 2018</xref>). A subsequent study revealed a putative role for epistatic D3R-dysbindin-1 interaction and executive function deficits in schizophrenia, highlighting the viability of D3R modulation as a treatment target for cognitive dysfunction (<xref ref-type="bibr" rid="B69">Leggio et al., 2019</xref>).</p>
<p>As outlined above, dysbindin disruption has also been proposed to underlie cognitive impairment observed in patients with Duchenne muscular dystrophy. A recent study investigated the effects of treatment with the cacao flavonoid (-)-epicatechin on brain dysbindin levels in the mdx mutant, a genetic mouse model of Duchenne muscular dystrophy; such treatment partially reversed genotype-dependent reductions in protein levels of the dystrophin-associated protein complex as well as dysbindin protein in PFC (<xref ref-type="bibr" rid="B37">Estrada-Mena et al., 2017</xref>). It was not reported whether this partial recovery was also observed at a behavioral level.</p>
<p>Investigation of transcriptional responses of developing hippocampal neurons in sdy/B6 mutants revealed not only the characteristic GABAergic interneuron deficiency but also changes in expression of the cation-chloride cotransporters NKCC1 and KCC2 during hippocampal development (<xref ref-type="bibr" rid="B67">Larimore et al., 2017</xref>). NKCC1 and KCC2 expression changes have been documented in the brains of patients with schizophrenia (<xref ref-type="bibr" rid="B56">Hyde et al., 2011</xref>; <xref ref-type="bibr" rid="B110">Sullivan et al., 2015</xref>) and NKCC1 agents, including the NKCC1 chloride antagonist bumetanide, have been studied in schizophrenia. Bumetanide reduced hallucinations in a case of schizophrenia (<xref ref-type="bibr" rid="B70">Lemonnier et al., 2016</xref>) and in a randomized, double-blind placebo-controlled clinical trial bumetanide treatment reduced hallucinations (<xref ref-type="bibr" rid="B93">Rahmanzadeh et al., 2017a</xref>) but did not exert broad antipsychotic activity (<xref ref-type="bibr" rid="B94">Rahmanzadeh et al., 2017b</xref>); cognition was not specifically investigated.</p>
<p>Consistent with the observed involvement of dysbindin in hippocampal and PFC glutamatergic function, a recent study investigated the impact of pharmacological enhancement of endogenous levels of brain-derived neurotrophic factor (BDNF) on dysbindin-related reduction of presynaptic calcium levels in PFC and social recognition memory in sdy/B6 mice (<xref ref-type="bibr" rid="B97">Saggu et al., 2013</xref>). Systemic treatment with fingolimod, a sphingosine 1-phosphate receptor modulator that has been shown to increase endogenous BDNF levels, attenuated deficits in recognition memory and sociability and in presynaptic calcium and BDNF levels in the PFC of sdy/B6 mice (<xref ref-type="bibr" rid="B6">Becker-Krail et al., 2017</xref>). BDNF levels in schizophrenia patients have been associated with impairment across multiple cognitive domains (<xref ref-type="bibr" rid="B76">Man et al., 2018</xref>; <xref ref-type="bibr" rid="B137">Yang et al., 2019</xref>). A recent review has highlighted that the BDNF gene should be prioritised for pharmacogenetic research into antipsychotic drugs and potential relevance to treatment response and adverse effects (<xref ref-type="bibr" rid="B53">Han and Deng, 2018</xref>).</p>
<p>Similarly, administration of CDPPB, a positive allosteric modulator of MGluR5, restored short-term recognition and spatial memory deficits (Morris water maze) in sdy/B6 mice (<xref ref-type="bibr" rid="B11">Bhardwaj et al., 2015</xref>). Given their effects on glutamatergic signalling, and particularly on NMDA receptor activity, MGluR5 modulators have been suggested to represent promising treatment targets for neuropsychiatric disorders that are characterized by cognitive deficits.</p>
<p>Expression of SREBP1, a sterol regulatory element binding protein (SREBP) that regulates the expression of genes implicated in biosynthesis of fatty acids, cholesterol, triglycerides, and phospholipids, is reduced in sdy/B6 mice and in schizophrenia patients; activation of SREBP1 and Arc, a protein implicated in memory and cognition, is reduced in sdy/B6 mice and both of these deficits were restored by treatment with clozapine, suggesting a link with cognitive dysfunction (<xref ref-type="bibr" rid="B25">Chen et al., 2016</xref>).</p>
</sec>
<sec id="s7">
<title>Dysbindin-1 and Beyond</title>
<p>Given the indicated role for dysbindin-1 in the pathophysiology of schizophrenia and associated cognitive impairment, it will be heuristic to search for drug targets and molecules that might influence its expression and functionality. Those studies that indicate relationships between dysbindin-1 function, neuronal and behavioral processes associated with the pathobiology of psychotic illness and responsivity to current D2R antagonist antipsychotic drugs are particularly provocative in this regard; this is because they offer the prospect of clues to identifying non-DAergic mechanisms of antipsychotic activity. Importantly, these concepts generalize beyond dysbindin-1 to other developmental regulators. For example, in addition to identifying a role for dysbindin-1A in the regulation of schizophrenia-related behavioral processes, including specialised delay/interference-dependent working memory (<xref ref-type="bibr" rid="B92">Petit et al., 2017</xref>), we have recently identified a role for the developmental gene and regulatory protein neuregulin-1 (NRG1) in a triad with miRNA-143 and D2R that was revealed through investigation of schizophrenia-related behavioral abnormalities induced by phencyclidine; miRNA-143 directly targeted to the 3’ un-translated region of NRG1 mRNA to reduce protein expression of NRG1 and the D2R modulated expression of NRG1 in PFC (<xref ref-type="bibr" rid="B128">Wang et al., 2019</xref>).</p>
<p>The issues reviewed above constitute a substantive basis for such a search. Furthermore, they offer tantalising glimpses into mechanisms and putative target sites relating to DTNBP1/dysbindin-1A and how these concepts might generalize to a broader spectrum of developmental genes and regulatory proteins implicated in the pathobiology of schizophrenia spectrum psychosis.</p>
</sec>
<sec id="s8">
<title>Author Contributions</title>
<p>JW, XZ, and CO’T reviewed the relevant literature and wrote this paper. JW, XZ, and CO’T revised the manuscript. All the authors listed agreed to the publication of this paper.</p>
</sec>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>This work was supported by Science Foundation Ireland through grant 07/IN.1/B960.</p>
</sec>
<sec id="s10">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Agnew-Blais</surname><given-names>J. C.</given-names></name><name><surname>Buka</surname><given-names>S. L.</given-names></name><name><surname>Fitzmaurice</surname><given-names>G. M.</given-names></name><name><surname>Smoller</surname><given-names>J. W.</given-names></name><name><surname>Goldstein</surname><given-names>J. M.</given-names></name><name><surname>Seidman</surname><given-names>L. J.</given-names></name></person-group> (<year>2015</year>). <article-title>Early childhood IQ trajectories in individuals later developing schizophrenia and affective psychoses in the New England family studies</article-title>. <source/>Schizophr. Bull.
<volume>41</volume>, <fpage>817</fpage>–<lpage>823</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbv027</pub-id>
<pub-id pub-id-type="pmid">25904723</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allen</surname><given-names>N. C.</given-names></name><name><surname>Bagade</surname><given-names>S.</given-names></name><name><surname>McQueen</surname><given-names>M. B.</given-names></name><name><surname>Ioannidis</surname><given-names>J. P.</given-names></name><name><surname>Kavvoura</surname><given-names>F. K.</given-names></name><name><surname>Khoury</surname><given-names>M. J.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database</article-title>. <source/>Nat. Genet.
<volume>40</volume>, <fpage>827</fpage>–<lpage>834</lpage>. <pub-id pub-id-type="doi">10.1038/ng.171</pub-id>
<pub-id pub-id-type="pmid">18583979</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Shammari</surname><given-names>A. R.</given-names></name><name><surname>Bhardwaj</surname><given-names>S. K.</given-names></name><name><surname>Musaelyan</surname><given-names>K.</given-names></name><name><surname>Srivastava</surname><given-names>L. K.</given-names></name><name><surname>Szele</surname><given-names>F. G.</given-names></name></person-group> (<year>2018</year>). <article-title>Schizophrenia-related dysbindin-1 gene is required for innate immune response and homeostasis in the developing subventricular zone</article-title>. <source/>NPJ Schizophr.
<volume>4</volume>, <fpage>15</fpage>. <pub-id pub-id-type="doi">10.1038/s41537-018-0057-5</pub-id>
<pub-id pub-id-type="pmid">30038210</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ayalew</surname><given-names>M.</given-names></name><name><surname>Le-Niculescu</surname><given-names>H.</given-names></name><name><surname>Levey</surname><given-names>D. F.</given-names></name><name><surname>Jain</surname><given-names>N.</given-names></name><name><surname>Changala</surname><given-names>B.</given-names></name><name><surname>Patel</surname><given-names>S. D.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction</article-title>. <source/>Mol. Psychiatry
<volume>17</volume>, <fpage>887</fpage>–<lpage>905</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2012.37</pub-id>
<pub-id pub-id-type="pmid">22584867</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baek</surname><given-names>J. H.</given-names></name><name><surname>Kim</surname><given-names>J. S.</given-names></name><name><surname>Ryu</surname><given-names>S.</given-names></name><name><surname>Oh</surname><given-names>S.</given-names></name><name><surname>Noh</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>W. K.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Association of genetic variations in DTNBP1 with cognitive function in schizophrenia patients and healthy subjects</article-title>. <source/>Am. J. Med. Genet. Part B: Neuropsychiatr. Genet.
<volume>7</volume>, <fpage>841</fpage>–<lpage>849</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.32091</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Becker-Krail</surname><given-names>D.</given-names></name><name><surname>Farrand</surname><given-names>A. Q.</given-names></name><name><surname>Boger</surname><given-names>H. A.</given-names></name><name><surname>Lavin</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Effects of fingolimod administration in a genetic model of cognitive deficits</article-title>. <source/>J. Neurosci. Res.
<volume>95</volume>, <fpage>1174</fpage>–<lpage>1181</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.23799</pub-id>
<pub-id pub-id-type="pmid">27439747</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benson</surname><given-names>M. A.</given-names></name><name><surname>Newey</surname><given-names>S. E.</given-names></name><name><surname>Martin-Rendon</surname><given-names>E.</given-names></name><name><surname>Hawkes</surname><given-names>R.</given-names></name><name><surname>Blake</surname><given-names>D. J.</given-names></name></person-group> (<year>2001</year>). <article-title>Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain</article-title>. <source/>J. Biol. Chem.
<volume>276</volume>, <fpage>24232</fpage>–<lpage>24241</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M010418200</pub-id>
<pub-id pub-id-type="pmid">11316798</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bergen</surname><given-names>S. E.</given-names></name><name><surname>Ploner</surname><given-names>A.</given-names></name><name><surname>Howrigan</surname><given-names>D.</given-names></name><name><surname>O’Donovan</surname><given-names>M. C.</given-names></name><name><surname>Smoller</surname><given-names>J. W.</given-names></name><etal></etal></person-group> (<year>2019</year>). <collab>CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium,</collab>
<article-title>Joint contributions of rare copy number variants and common SNPs to risk for schizophrenia</article-title>. <source/>Am. J. Psychiatry
<volume>176</volume>, <fpage>29</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2018.17040467</pub-id>
<pub-id pub-id-type="pmid">30392412</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>H. G.</given-names></name><name><surname>Steiner</surname><given-names>J.</given-names></name><name><surname>Guest</surname><given-names>P. C.</given-names></name><name><surname>Dobrowolny</surname><given-names>H.</given-names></name><name><surname>Bogerts</surname><given-names>B.</given-names></name></person-group> (<year>2015</year>). <article-title>Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy</article-title>. <source/>Schizophr. Res.
<volume>161</volume>, <fpage>4</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2014.03.035</pub-id>
<pub-id pub-id-type="pmid">24948484</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>S. K.</given-names></name><name><surname>Baharnoori</surname><given-names>M.</given-names></name><name><surname>Sharif-Askari</surname><given-names>B.</given-names></name><name><surname>Kamath</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>S.</given-names></name><name><surname>Srivastava</surname><given-names>L. K.</given-names></name></person-group> (<year>2009</year>). <article-title>Behavioral characterization of dysbindin-1 deficient sandy mice</article-title>. <source/>Behav. Brain Res.
<volume>197</volume>, <fpage>435</fpage>–<lpage>441</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2008.10.011</pub-id>
<pub-id pub-id-type="pmid">18984010</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>S. K.</given-names></name><name><surname>Ryan</surname><given-names>R. T.</given-names></name><name><surname>Wong</surname><given-names>T. P.</given-names></name><name><surname>Srivastava</surname><given-names>L. K.</given-names></name></person-group> (<year>2015</year>). <article-title>Loss of dysbindin-1, a risk gene for schizophrenia, leads to impaired group 1 metabotropic glutamate receptor function in mice</article-title>. <source/>Front. Behav. Neurosci.
<volume>9</volume>, <elocation-id>72</elocation-id>. <pub-id pub-id-type="doi">10.3389/fnbeh.2015.00072</pub-id>
<pub-id pub-id-type="pmid">25859193</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Birnbaum</surname><given-names>R.</given-names></name><name><surname>Weinberger</surname><given-names>D. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Genetic insights into the neurodevelopmental origins of schizophrenia</article-title>. <source/>Nat. Rev. Neurosci.
<volume>18</volume>, <fpage>727</fpage>–<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1038/nrn.2017.125</pub-id>
<pub-id pub-id-type="pmid">29070826</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blake</surname><given-names>D. J.</given-names></name><name><surname>Kröger</surname><given-names>S.</given-names></name></person-group> (<year>2000</year>). <article-title>The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle</article-title>? <source/>Trends Neurosci.
<volume>23</volume>, <fpage>92</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/s0166-2236(99)01510-6</pub-id>
<pub-id pub-id-type="pmid">10675908</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boyle</surname><given-names>E. A.</given-names></name><name><surname>Li</surname><given-names>Y. I.</given-names></name><name><surname>Pritchard</surname><given-names>J. K.</given-names></name></person-group> (<year>2017</year>). <article-title>An expanded view of complex traits: from polygenic to omnigenic</article-title>. <source/>Cell
<volume>169</volume>, <fpage>1177</fpage>–<lpage>1186</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.05.038</pub-id>
<pub-id pub-id-type="pmid">28622505</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bradshaw</surname><given-names>N. J.</given-names></name><name><surname>Korth</surname><given-names>C.</given-names></name></person-group> (<year>2019</year>). <article-title>Protein misassembly and aggregation as potential convergence points for nongenetic causes of chronic mental illness</article-title>. <source/>Mol. Psychiatry
<volume>24</volume>, <fpage>936</fpage>–<lpage>951</lpage>. <pub-id pub-id-type="doi">10.1038/s41380-018-0133-2</pub-id>
<pub-id pub-id-type="pmid">30089789</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bray</surname><given-names>N. J.</given-names></name><name><surname>Buckland</surname><given-names>P. R.</given-names></name><name><surname>Owen</surname><given-names>M. J.</given-names></name><name><surname>O’Donovan</surname><given-names>M. C.</given-names></name></person-group> (<year>2003</year>). <article-title>Cis-acting variation in the expression of a high proportion of genes in human brain</article-title>. <source/>Hum. Genet.
<volume>113</volume>, <fpage>149</fpage>–<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-003-0956-y</pub-id>
<pub-id pub-id-type="pmid">12728311</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bray</surname><given-names>N. J.</given-names></name><name><surname>Preece</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>N. M.</given-names></name><name><surname>Moskvina</surname><given-names>V.</given-names></name><name><surname>Buckland</surname><given-names>P. R.</given-names></name><name><surname>Owen</surname><given-names>M. J.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression</article-title>. <source/>Hum. Mol. Genet.
<volume>14</volume>, <fpage>1947</fpage>–<lpage>1954</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddi199</pub-id>
<pub-id pub-id-type="pmid">15917270</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bray</surname><given-names>N. J.</given-names></name><name><surname>Holmans</surname><given-names>P. A.</given-names></name><name><surname>van den Bree</surname><given-names>M. B.</given-names></name><name><surname>Jones</surname><given-names>L.</given-names></name><name><surname>Elliston</surname><given-names>L. A.</given-names></name><name><surname>Hughes</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Cis-and trans-loci influence expression of the schizophrenia susceptibility gene DTNBP1</article-title>. <source/>Hum. Mol. Genet.
<volume>17</volume>, <fpage>1169</fpage>–<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddn006</pub-id>
<pub-id pub-id-type="pmid">18182443</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burdick</surname><given-names>K. E.</given-names></name><name><surname>Lencz</surname><given-names>T.</given-names></name><name><surname>Funke</surname><given-names>B.</given-names></name><name><surname>Finn</surname><given-names>C. T.</given-names></name><name><surname>Szeszko</surname><given-names>P. R.</given-names></name><name><surname>Kane</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Genetic variation in DTNBP1 influences general cognitive ability</article-title>. <source/>Hum. Mol. Genet.
<volume>15</volume>, <fpage>1563</fpage>–<lpage>1568</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddi48</pub-id>
<pub-id pub-id-type="pmid">16415041</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burdick</surname><given-names>K. E.</given-names></name><name><surname>Goldberg</surname><given-names>T. E.</given-names></name><name><surname>Funke</surname><given-names>B.</given-names></name><name><surname>Bates</surname><given-names>J. A.</given-names></name><name><surname>Lencz</surname><given-names>T.</given-names></name><name><surname>Kucherlapati</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>DTNBP1 genotype influences cognitive decline in schizophrenia</article-title>. <source/>Schizophr. Res.
<volume>89</volume>, <fpage>169</fpage>–<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2006.09.008</pub-id>
<pub-id pub-id-type="pmid">17074466</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carlson</surname><given-names>G. C.</given-names></name><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Halene</surname><given-names>T. B.</given-names></name><name><surname>Gandal</surname><given-names>M. J.</given-names></name><name><surname>Kazi</surname><given-names>H. A.</given-names></name><name><surname>Schlosser</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>108</volume>, <fpage>E962</fpage>–<lpage>E970</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1109625108</pub-id>
<pub-id pub-id-type="pmid">21969553</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carr</surname><given-names>G. V.</given-names></name><name><surname>Jenkins</surname><given-names>K. A.</given-names></name><name><surname>Weinberger</surname><given-names>D. R.</given-names></name><name><surname>Papaleo</surname><given-names>F.</given-names></name></person-group> (<year>2012</year>). <article-title>Loss of dysbindin-1 in mice impairs reward-based operant learning by increasing impulsive and compulsive behavior</article-title>. <source/>Behav. Brain Res.
<volume>241</volume>, <fpage>173</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2012.12.021</pub-id>
<pub-id pub-id-type="pmid">23261874</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>E. H.</given-names></name><name><surname>Fernando</surname><given-names>K.</given-names></name><name><surname>Yeung</surname><given-names>L. W. E.</given-names></name><name><surname>Barbari</surname><given-names>K.</given-names></name><name><surname>Chandon</surname><given-names>T. S.</given-names></name><name><surname>Malhotra</surname><given-names>A. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Single point mutation on the gene encoding dysbindin results in recognition deficits</article-title>. <source/>Genes Brain Behav.
<volume>17</volume>, <fpage>e12449</fpage>. <pub-id pub-id-type="doi">10.1111/gbb.12449</pub-id>
<pub-id pub-id-type="pmid">29227583</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheli</surname><given-names>V. T.</given-names></name><name><surname>Daniels</surname><given-names>R. W.</given-names></name><name><surname>Godoy</surname><given-names>R.</given-names></name><name><surname>Hoyle</surname><given-names>D. J.</given-names></name><name><surname>Kandachar</surname><given-names>V.</given-names></name><name><surname>Starcevic</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Genetic modifiers of abnormal organelle biogenesis in a Drosophila model of BLOC-1 deficiency</article-title>. <source/>Hum. Mol. Genet.
<volume>19</volume>, <fpage>861</fpage>–<lpage>878</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddp555</pub-id>
<pub-id pub-id-type="pmid">20015953</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Bang</surname><given-names>S.</given-names></name><name><surname>McMullen</surname><given-names>M. F.</given-names></name><name><surname>Kazi</surname><given-names>H.</given-names></name><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Ho</surname><given-names>M. X.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Neuronal activity-induced sterol regulatory element binding protein-1 (SREBP1) is disrupted in dysbindin-null mice-potential link to cognitive impairment in schizophrenia</article-title>. <source/>Mol. Neurobiol.
<volume>54</volume>, <fpage>1699</fpage>–<lpage>1709</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-9773-x</pub-id>
<pub-id pub-id-type="pmid">26873854</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chow</surname><given-names>T. J.</given-names></name><name><surname>Tee</surname><given-names>S. F.</given-names></name><name><surname>Loh</surname><given-names>S. Y.</given-names></name><name><surname>Yong</surname><given-names>H. S.</given-names></name><name><surname>Abu Bakar</surname><given-names>A. K.</given-names></name><name><surname>Tang</surname><given-names>P. Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Variants in ZNF804A and DTNBP1 assessed for cognitive impairment in schizophrenia using a multiplex family-based approach</article-title>. <source/>Psychiatry Res.
<volume>270</volume>, <fpage>1166</fpage>–<lpage>1167</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2018.04.051</pub-id>
<pub-id pub-id-type="pmid">29754893</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Correa</surname><given-names>D. D.</given-names></name><name><surname>Satagopan</surname><given-names>J.</given-names></name><name><surname>Cheung</surname><given-names>K.</given-names></name><name><surname>Arora</surname><given-names>A. K.</given-names></name><name><surname>Kryza-Lacombe</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors</article-title>. <source/>Neuro-Oncol.
<volume>18</volume>, <fpage>1425</fpage>–<lpage>1433</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/now057</pub-id>
<pub-id pub-id-type="pmid">27091610</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cox</surname><given-names>M.</given-names></name><name><surname>Tucker</surname><given-names>A.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Richer</surname><given-names>D.</given-names></name><name><surname>Yeh</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6J genetic background</article-title>. <source/>Genes Brain Behav.
<volume>8</volume>, <fpage>390</fpage>–<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2009.00477.x</pub-id>
<pub-id pub-id-type="pmid">19220483</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dawson</surname><given-names>N.</given-names></name><name><surname>Morris</surname><given-names>B. J.</given-names></name><name><surname>Pratt</surname><given-names>J. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Functional brain connectivity phenotypes for schizophrenia drug discovery</article-title>. <source/>J. Psychopharmacol.
<volume>29</volume>, <fpage>169</fpage>–<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1177/0269881114563635</pub-id>
<pub-id pub-id-type="pmid">25567554</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dell’Angelica</surname><given-names>E. C.</given-names></name></person-group> (<year>2004</year>). <article-title>The building BLOC(k)s of lysosomes and related organelles</article-title>. <source/>Curr. Op. Cell Biol.
<volume>16</volume>, <fpage>458</fpage>–<lpage>464</lpage>. <pub-id pub-id-type="doi">10.1016/j.ceb.2004.05.001</pub-id>
<pub-id pub-id-type="pmid">15261680</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Diamantopoulou</surname><given-names>A.</given-names></name><name><surname>Gogos</surname><given-names>J. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Neurocognitive and perceptual processing in genetic mouse models of schizophrenia: emerging lessons</article-title>. <source/>Neuroscientist Jan
<volume>17</volume>. 1073858418819435
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dickman</surname><given-names>D. K.</given-names></name><name><surname>Davis</surname><given-names>G. W.</given-names></name></person-group> (<year>2009</year>). <article-title>The schizophrenia susceptibility gene dysbindin controls synaptic homeostasis</article-title>. <source/>Science
<volume>326</volume>, <fpage>1127</fpage>–<lpage>1130</lpage>. <pub-id pub-id-type="doi">10.1126/science.1179685</pub-id>
<pub-id pub-id-type="pmid">19965435</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donohoe</surname><given-names>G.</given-names></name><name><surname>Morris</surname><given-names>D. W.</given-names></name><name><surname>Clarke</surname><given-names>S.</given-names></name><name><surname>McGhee</surname><given-names>K. A.</given-names></name><name><surname>Schwaiger</surname><given-names>S.</given-names></name><name><surname>Nangle</surname><given-names>J. M.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study</article-title>. <source/>Neuropsychologia
<volume>45</volume>, <fpage>454</fpage>–<lpage>458</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2006.06.016</pub-id>
<pub-id pub-id-type="pmid">16930638</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donohoe</surname><given-names>G.</given-names></name><name><surname>Morris</surname><given-names>D. W.</given-names></name><name><surname>De Sanctis</surname><given-names>P.</given-names></name><name><surname>Magno</surname><given-names>E.</given-names></name><name><surname>Montesi</surname><given-names>J. L.</given-names></name><name><surname>Garavan</surname><given-names>H. P.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Early visual processing deficits in dysbindin-associated schizophrenia</article-title>. <source/>Biol. Psychiatry
<volume>63</volume>, <fpage>484</fpage>–<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2007.07.022</pub-id>
<pub-id pub-id-type="pmid">17945199</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Donohoe</surname><given-names>G.</given-names></name><name><surname>Frodl</surname><given-names>T.</given-names></name><name><surname>Morris</surname><given-names>D.</given-names></name><name><surname>Spoletini</surname><given-names>I.</given-names></name><name><surname>Cannon</surname><given-names>D. M.</given-names></name><name><surname>Cherubini</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Reduced occipital and prefrontal brain volumes in dysbindin-associated schizophrenia</article-title>. <source/>Neuropsychopharmacology
<volume>35</volume>, <fpage>368</fpage>–<lpage>373</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2009.140</pub-id>
<pub-id pub-id-type="pmid">19794403</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Enriquez-Barreto</surname><given-names>L.</given-names></name><name><surname>Morales</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia</article-title>. <source/>Mol. Cell Ther.
<volume>4</volume>, <fpage>2</fpage>. <pub-id pub-id-type="doi">10.1186/s40591-016-0047-9</pub-id>
<pub-id pub-id-type="pmid">26877878</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Estrada-Mena</surname><given-names>F. J.</given-names></name><name><surname>Rodriguez</surname><given-names>A.</given-names></name><name><surname>Mendoza-Lorenzo</surname><given-names>P.</given-names></name><name><surname>Neri-Gomez</surname><given-names>T.</given-names></name><name><surname>Manjarrez-Gutierrez</surname><given-names>G.</given-names></name><name><surname>Perez-Ortiz</surname><given-names>A. C.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Effects of (-)-epicatechin on frontal cortex DAPC and dysbindin of the mdx mice</article-title>. <source/>Neurosci. Lett.
<volume>658</volume>, <fpage>142</fpage>–<lpage>149</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2017.08.056</pub-id>
<pub-id pub-id-type="pmid">28855126</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farrell</surname><given-names>M. S.</given-names></name><name><surname>Werge</surname><given-names>T.</given-names></name><name><surname>Sklar</surname><given-names>P.</given-names></name><name><surname>Owen</surname><given-names>M. J.</given-names></name><name><surname>Ophoff</surname><given-names>R. A.</given-names></name><name><surname>O’Donovan</surname><given-names>M. C.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Evaluating historical candidate genes for schizophrenia</article-title>. <source/>Mol. Psychiatry
<volume>20</volume>, <fpage>555</fpage>–<lpage>562</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2015.16</pub-id>
<pub-id pub-id-type="pmid">25754081</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y.-Q.</given-names></name><name><surname>Zhou</surname><given-names>Z.-Y.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>X.-L.</given-names></name><name><surname>Hao</surname><given-names>C.-J.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia</article-title>. <source/>Schizophr. Res.
<volume>106</volume>, <fpage>218</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2008.07.018</pub-id>
<pub-id pub-id-type="pmid">18774265</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fung</surname><given-names>S. J.</given-names></name><name><surname>Sivagnanasundaram</surname><given-names>S.</given-names></name><name><surname>Weickert</surname><given-names>C. S.</given-names></name></person-group> (<year>2011</year>). <article-title>Lack of change in markers of presynatic terminal abundance alongside subtle reductions in markers of presynaptic terminal plasticity in prefrontal cortex of schizophrenia patients</article-title>. <source/>Biol. Psychiatry
<volume>69</volume>, <fpage>71</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2010.09.036</pub-id>
<pub-id pub-id-type="pmid">21145444</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Genovese</surname><given-names>G.</given-names></name><name><surname>Fromer</surname><given-names>M.</given-names></name><name><surname>Stahl</surname><given-names>E. A.</given-names></name><name><surname>Ruderfer</surname><given-names>D. M.</given-names></name><name><surname>Chambert</surname><given-names>K.</given-names></name><name><surname>Landén</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia</article-title>. <source/>Nat. Neurosci.
<volume>19</volume>, <fpage>1433</fpage>–<lpage>1441</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4402</pub-id>
<pub-id pub-id-type="pmid">27694994</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gerrish</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>H.</given-names></name><name><surname>Moskvina</surname><given-names>V.</given-names></name><name><surname>Owen</surname><given-names>M. J.</given-names></name><name><surname>O’Donovan</surname><given-names>M. C.</given-names></name><name><surname>Williams</surname><given-names>N. M.</given-names></name></person-group> (<year>2009</year>). <article-title>An examination of MUTED as a schizophrenia susceptibility gene</article-title>. <source/>Schizophr. Res.
<volume>107</volume>, <fpage>110</fpage>–<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2008.08.011</pub-id>
<pub-id pub-id-type="pmid">18815010</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ghiani</surname><given-names>C.</given-names></name><name><surname>Starcevic</surname><given-names>M.</given-names></name><name><surname>Rodriguez-Fernandez</surname><given-names>I.</given-names></name><name><surname>Nazarian</surname><given-names>R.</given-names></name><name><surname>Cheli</surname><given-names>V.</given-names></name><name><surname>Chan</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>The dysbindin-containing complex (BLOC-1) in brain: developmental regulation, interaction with SNARE proteins and role in neurite outgrowth</article-title>. <source/>Mol. Psychiatry
<volume>15</volume>, <fpage>204</fpage>–<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2009.58</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glen</surname><given-names>W.B.</given-names><suffix>Jr</suffix></name><name><surname>Horowitz</surname><given-names>B.</given-names></name><name><surname>Carlson</surname><given-names>G. C.</given-names></name><name><surname>Cannon</surname><given-names>T. D.</given-names></name><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Jentsch</surname><given-names>J. D.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Dysbindin-1 loss compromises NMDAR-dependent synaptic plasticity and contextual fear conditioning</article-title>. <source/>Hippocampus
<volume>24</volume>, <fpage>204</fpage>–<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.22215</pub-id>
<pub-id pub-id-type="pmid">24446171</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gokhale</surname><given-names>A.</given-names></name><name><surname>Mullin</surname><given-names>A. P.</given-names></name><name><surname>Zlatic</surname><given-names>S. A.</given-names></name><name><surname>Easley</surname><given-names>C. A.</given-names><suffix>4th</suffix></name><name><surname>Merritt</surname><given-names>M. E.</given-names></name><name><surname>Raj</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>The N-ethylmaleimide-sensitive factor and dysbindin interact to modulate synaptic plasticity</article-title>. <source/>J. Neurosci.
<volume>35</volume>, <fpage>7643</fpage>–<lpage>7653</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4724-14.2015</pub-id>
<pub-id pub-id-type="pmid">25972187</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gokhale</surname><given-names>A.</given-names></name><name><surname>Hartwig</surname><given-names>C.</given-names></name><name><surname>Freeman</surname><given-names>A. H.</given-names></name><name><surname>Das</surname><given-names>R.</given-names></name><name><surname>Zlatic</surname><given-names>S. A.</given-names></name><name><surname>Vistein</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>The proteome of BLOC-1 genetic defects identifies the Arp2/3 Actin polymerization complex to function downstream of the schizophrenia susceptibility factor dysbindin at the synapse</article-title>. <source/>J. Neurosci.
<volume>36</volume>, <fpage>12393</fpage>–<lpage>12411</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1321-16.2016</pub-id>
<pub-id pub-id-type="pmid">27927957</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gonzalez-Islas</surname><given-names>C.</given-names></name><name><surname>Hablitz</surname><given-names>J. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Dopamine enhances EPSCs in layer II-III pyramidal neurons in rat prefrontal cortex</article-title>. <source/>J. Neurosci.
<volume>23</volume>, <fpage>867</fpage>–<lpage>875</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-03-00867.2003</pub-id>
<pub-id pub-id-type="pmid">12574415</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grady</surname><given-names>R. M.</given-names></name><name><surname>Wozniak</surname><given-names>D. F.</given-names></name><name><surname>Ohlemiller</surname><given-names>K. K.</given-names></name><name><surname>Sanes</surname><given-names>J. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Cerebellar synaptic defects and abnormal motor behavior in mice lacking α-and β-dystrobrevin</article-title>. <source/>J. Neurosci.
<volume>26</volume>, <fpage>2841</fpage>–<lpage>2851</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4823-05.2006</pub-id>
<pub-id pub-id-type="pmid">16540561</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Green</surname><given-names>M. F.</given-names></name><name><surname>Horan</surname><given-names>W. P.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Nonsocial and social cognition in schizophrenia: current evidence and future directions</article-title>. <source/>World Psychiatry
<volume>18</volume>, <fpage>146</fpage>–<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1002/wps.20624</pub-id>
<pub-id pub-id-type="pmid">31059632</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guloksuz</surname><given-names>S.</given-names></name><name><surname>Pries</surname><given-names>L. K.</given-names></name><name><surname>Delespaul</surname><given-names>P.</given-names></name><name><surname>Kenis</surname><given-names>G.</given-names></name><name><surname>Luykx</surname><given-names>J. J.</given-names></name><name><surname>Lin</surname><given-names>B. D.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study</article-title>. <source/>World Psychiatry
<volume>18</volume>, <fpage>173</fpage>–<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1002/wps.20629</pub-id>
<pub-id pub-id-type="pmid">31059627</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>A.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Riley</surname><given-names>B.</given-names></name><name><surname>Thiselton</surname><given-names>D.</given-names></name><name><surname>Kendler</surname><given-names>K.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name></person-group> (<year>2008</year>). <article-title>The dystrobrevin-binding protein 1 gene: features and networks</article-title>. <source/>Mol. Psychiatry
<volume>14</volume>, <fpage>18</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2008.88</pub-id>
<pub-id pub-id-type="pmid">18663367</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>A. Y.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Riley</surname><given-names>B. P.</given-names></name><name><surname>Thiselton</surname><given-names>D. L.</given-names></name><name><surname>Kendler</surname><given-names>K. S.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>The dystrobrevin-binding protein 1 gene: features and networks</article-title>. <source/>Mol. Psychiatry.
<volume>14</volume>, <fpage>18</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2008.88</pub-id>
<pub-id pub-id-type="pmid">18663367</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Deng</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia</article-title>. <source/>Neurosci. Lett.
<volume>9</volume>, <fpage>133870</fpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2018.10.015</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hartwig</surname><given-names>C.</given-names></name><name><surname>Monis</surname><given-names>W. J.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Dickman</surname><given-names>D. K.</given-names></name><name><surname>Pazour</surname><given-names>G. J.</given-names></name><name><surname>Faundez</surname><given-names>V.</given-names></name></person-group> (<year>2018</year>). <article-title>Neurodevelopmental disease mechanisms, primary cilia, and endosomes converge on the BLOC-1 and BORC complexes</article-title>. <source/>Dev. Neurobiol.
<volume>78</volume>, <fpage>311</fpage>–<lpage>330</lpage>. <pub-id pub-id-type="doi">10.1002/dneu.22542</pub-id>
<pub-id pub-id-type="pmid">28986965</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hilker</surname><given-names>R.</given-names></name><name><surname>Helenius</surname><given-names>D.</given-names></name><name><surname>Fagerlund</surname><given-names>B.</given-names></name><name><surname>Skytthe</surname><given-names>A.</given-names></name><name><surname>Christensen</surname><given-names>K.</given-names></name><name><surname>Werge</surname><given-names>T. M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish twin register</article-title>. <source/>Biol. Psychiatry
<volume>83</volume>, <fpage>492</fpage>–<lpage>498</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2017.08.017</pub-id>
<pub-id pub-id-type="pmid">28987712</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hyde</surname><given-names>T. M.</given-names></name><name><surname>Lipska</surname><given-names>B. K.</given-names></name><name><surname>Ali</surname><given-names>T.</given-names></name><name><surname>Mathew</surname><given-names>S. V.</given-names></name><name><surname>Law</surname><given-names>A. J.</given-names></name><name><surname>Metitiri</surname><given-names>O. E.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia</article-title>. <source/>J. Neurosci.
<volume>31</volume>, <fpage>11088</fpage>–<lpage>11095</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1234-11.2011</pub-id>
<pub-id pub-id-type="pmid">21795557</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iizuka</surname><given-names>Y.</given-names></name><name><surname>Sei</surname><given-names>Y.</given-names></name><name><surname>Weinberger</surname><given-names>D. R.</given-names></name><name><surname>Straub</surname><given-names>R. E.</given-names></name></person-group> (<year>2007</year>). <article-title>Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization</article-title>. <source/>J. Neurosci.
<volume>27</volume>, <fpage>12390</fpage>–<lpage>12395</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1689-07.2007</pub-id>
<pub-id pub-id-type="pmid">17989303</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jentsch</surname><given-names>J. D.</given-names></name><name><surname>Trantham-Davidson</surname><given-names>H.</given-names></name><name><surname>Jairl</surname><given-names>C.</given-names></name><name><surname>Tinsley</surname><given-names>M.</given-names></name><name><surname>Cannon</surname><given-names>T. D.</given-names></name><name><surname>Lavin</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice</article-title>. <source/>Neuropsychopharmacology
<volume>34</volume>, <fpage>2601</fpage>–<lpage>2608</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2009.90</pub-id>
<pub-id pub-id-type="pmid">19641486</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>H. J.</given-names></name><name><surname>Stergiakouli</surname><given-names>E.</given-names></name><name><surname>Tansey</surname><given-names>K. E.</given-names></name><name><surname>Hubbard</surname><given-names>L.</given-names></name><name><surname>Heron</surname><given-names>J.</given-names></name><name><surname>Cannon</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Phenotypic manifestation of genetic risk for schizophrenia during adolescence in the general population</article-title>. <source/>JAMA Psychiatry
<volume>73</volume>, <fpage>221</fpage>–<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2015.3058</pub-id>
<pub-id pub-id-type="pmid">26818099</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kahn</surname><given-names>R. S.</given-names></name><name><surname>Keefe</surname><given-names>R. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Schizophrenia is a cognitive illness: time for a change in focus</article-title>. <source/>JAMA Psychiatry
<volume>70</volume>, <fpage>1107</fpage>–<lpage>1112</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.155</pub-id>
<pub-id pub-id-type="pmid">23925787</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kirov</surname><given-names>G.</given-names></name><name><surname>Pocklington</surname><given-names>A. J.</given-names></name><name><surname>Holmans</surname><given-names>P.</given-names></name><name><surname>Ivanov</surname><given-names>D.</given-names></name><name><surname>Ikeda</surname><given-names>M.</given-names></name><name><surname>Ruderfer</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia</article-title>. <source/>Mol. Psychiatry
<volume>17</volume>, <fpage>142</fpage>–<lpage>153</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2011.154</pub-id>
<pub-id pub-id-type="pmid">22083728</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K.</given-names></name><name><surname>Umeda-Yano</surname><given-names>S.</given-names></name><name><surname>Yamamori</surname><given-names>H.</given-names></name><name><surname>Takeda</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Hashimoto</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Correlated alterations in serotonergic and dopaminergic modulations at the hippocampal mossy fiber synapse in mice lacking dysbindin</article-title>. <source/>PloS One
<volume>6</volume>, <fpage>e18113</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0018113</pub-id>
<pub-id pub-id-type="pmid">21448290</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Konopaske</surname><given-names>G. T.</given-names></name><name><surname>Balu</surname><given-names>D. T.</given-names></name><name><surname>Presti</surname><given-names>K. T.</given-names></name><name><surname>Chan</surname><given-names>G.</given-names></name><name><surname>Benes</surname><given-names>F. M.</given-names></name><name><surname>Coyle</surname><given-names>J. T.</given-names></name></person-group> (<year>2018</year>). <article-title>Dysbindin-1 contributes to prefrontal cortical dendritic arbor pathology in schizophrenia</article-title>. <source/>Schizophr. Res.
<volume>201</volume>, <fpage>270</fpage>–<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2018.04.042</pub-id>
<pub-id pub-id-type="pmid">29759351</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotlar</surname><given-names>A. V.</given-names></name><name><surname>Mercer</surname><given-names>K. B.</given-names></name><name><surname>Zwick</surname><given-names>M. E.</given-names></name><name><surname>Mulle</surname><given-names>J. G.</given-names></name></person-group> (<year>2015</year>). <article-title>New discoveries in schizophrenia genetics reveal neurobiological pathways: a review of recent findings</article-title>. <source/>Eur. J. Med. Genet.
<volume>58</volume>, <fpage>704</fpage>–<lpage>714</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmg.2015.10.008</pub-id>
<pub-id pub-id-type="pmid">26493318</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kubota</surname><given-names>K.</given-names></name><name><surname>Kumamoto</surname><given-names>N.</given-names></name><name><surname>Matsuzaki</surname><given-names>S.</given-names></name><name><surname>Hashimoto</surname><given-names>R.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name><name><surname>Okuda</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Dysbindin engages in c-Jun N-terminal kinase activity and cytoskeletal organization</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>379</volume>, <fpage>191</fpage>–<lpage>195</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2008.12.017</pub-id>
<pub-id pub-id-type="pmid">19094965</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larimore</surname><given-names>J.</given-names></name><name><surname>Zlatic</surname><given-names>S. A.</given-names></name><name><surname>Gokhale</surname><given-names>A.</given-names></name><name><surname>Tornieri</surname><given-names>K.</given-names></name><name><surname>Singleton</surname><given-names>K. S.</given-names></name><name><surname>Mullin</surname><given-names>A. P.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Mutations in the BLOC-1 subunits dysbindin and muted generate divergent and dosage-dependent phenotypes</article-title>. <source/>J. Biol. Chem.
<volume>289</volume>, <fpage>14291</fpage>–<lpage>14300</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.553750</pub-id>
<pub-id pub-id-type="pmid">24713699</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Larimore</surname><given-names>J.</given-names></name><name><surname>Zlatic</surname><given-names>S. A.</given-names></name><name><surname>Arnold</surname><given-names>M.</given-names></name><name><surname>Singleton</surname><given-names>K. S.</given-names></name><name><surname>Cross</surname><given-names>R.</given-names></name><name><surname>Rudolph</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Dysbindin deficiency modifies the expression of GABA neuron and ion permeation transcripts in the developing hippocampus</article-title>. <source/>Front. Genet.
<volume>8</volume>, <elocation-id>28</elocation-id>. <pub-id pub-id-type="doi">10.3389/fgene.2017.00028</pub-id>
<pub-id pub-id-type="pmid">28344592</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>H. H.</given-names></name><name><surname>Nemecek</surname><given-names>D.</given-names></name><name><surname>Schindler</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>W. J.</given-names></name><name><surname>Ghirlando</surname><given-names>R.</given-names></name><name><surname>Steven</surname><given-names>A. C.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Assembly and architecture of biogenesis of lysosome-related organelles complex-1 (BLOC-1)</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>5882</fpage>–<lpage>5890</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.325746</pub-id>
<pub-id pub-id-type="pmid">22203680</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leggio</surname><given-names>G. M.</given-names></name><name><surname>Torrisi</surname><given-names>S. A.</given-names></name><name><surname>Mastrogiacomo</surname><given-names>R.</given-names></name><name><surname>Mauro</surname><given-names>D.</given-names></name><name><surname>Chisari</surname><given-names>M.</given-names></name><name><surname>Devroye</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans</article-title>. <source/>Mol. Psychiatry. <pub-id pub-id-type="doi">10.1038/s41380-019-0511-4</pub-id>
</mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lemonnier</surname><given-names>E.</given-names></name><name><surname>Lazartigues</surname><given-names>A.</given-names></name><name><surname>Ben-Ari</surname><given-names>Y.</given-names></name></person-group> (<year>2016</year>). <article-title>Treating schizophrenia with the diuretic bumetanide: a case report</article-title>. <source/>Clin. Neuropharmacol.
<volume>39</volume>, <fpage>115</fpage>–<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1097/WNF.0000000000000136</pub-id>
<pub-id pub-id-type="pmid">26966887</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>D. A.</given-names></name><name><surname>Hashimoto</surname><given-names>T.</given-names></name><name><surname>Morris</surname><given-names>H. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Cell and receptor type-specific alterations in markers of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia</article-title>. <source/>Neurotox. Res.
<volume>14</volume>, <fpage>237</fpage>–<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1007/BF03033813</pub-id>
<pub-id pub-id-type="pmid">19073429</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Oiso</surname><given-names>N.</given-names></name><name><surname>Novak</surname><given-names>E. K.</given-names></name><name><surname>Gautam</surname><given-names>R.</given-names></name><name><surname>O’Brien</surname><given-names>E. P.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1)</article-title>. <source/>Nat. Genet.
<volume>35</volume>, <fpage>84</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1038/ng1229</pub-id>
<pub-id pub-id-type="pmid">12923531</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Rusiniak</surname><given-names>M. E.</given-names></name><name><surname>Chintala</surname><given-names>S.</given-names></name><name><surname>Gautam</surname><given-names>R.</given-names></name><name><surname>Novak</surname><given-names>E. K.</given-names></name><name><surname>Swank</surname><given-names>R. T.</given-names></name></person-group> (<year>2004</year>). <article-title>Murine Hermansky–Pudlak syndrome genes: regulators of lysosome-related organelles</article-title>. <source/>Bioessays
<volume>26</volume>, <fpage>616</fpage>–<lpage>628</lpage>. <pub-id pub-id-type="doi">10.1002/bies.20042</pub-id>
<pub-id pub-id-type="pmid">15170859</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luciano</surname><given-names>M.</given-names></name><name><surname>Miyajima</surname><given-names>F.</given-names></name><name><surname>Lind</surname><given-names>P. A.</given-names></name><name><surname>Bates</surname><given-names>T. C.</given-names></name><name><surname>Horan</surname><given-names>M.</given-names></name><name><surname>Harris</surname><given-names>S. E.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Variation in the dysbindin gene and normal cognitive function in three independent population samples</article-title>. <source/>Genes Brain Behav.
<volume>8</volume>, <fpage>218</fpage>–<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2008.00462.x</pub-id>
<pub-id pub-id-type="pmid">19077176</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>D.</given-names></name><name><surname>Sebat</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>CNVs: harbingers of a rare variant revolution in psychiatric genetics</article-title>. <source/>Cell
<volume>148</volume>, <fpage>1223</fpage>–<lpage>1241</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.02.039</pub-id>
<pub-id pub-id-type="pmid">22424231</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Man</surname><given-names>L.</given-names></name><name><surname>Lv</surname><given-names>X.</given-names></name><name><surname>Du</surname><given-names>X. D.</given-names></name><name><surname>Yin</surname><given-names>G.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia</article-title>. <source/>Psychiatry Res.
<volume>263</volume>, <fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2018.02.034</pub-id>
<pub-id pub-id-type="pmid">29482040</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manning</surname><given-names>B. D.</given-names></name><name><surname>Cantley</surname><given-names>L. C.</given-names></name></person-group> (<year>2007</year>). <article-title>AKT/PKB signaling: navigating downstream</article-title>. <source/>Cell
<volume>129</volume>, <fpage>1261</fpage>–<lpage>1274</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2007.06.009</pub-id>
<pub-id pub-id-type="pmid">17604717</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manolio</surname><given-names>T. A.</given-names></name><name><surname>Collins</surname><given-names>F. S.</given-names></name><name><surname>Cox</surname><given-names>N. J.</given-names></name><name><surname>Goldstein</surname><given-names>D. B.</given-names></name><name><surname>Hindorff</surname><given-names>L. A.</given-names></name><name><surname>Hunter</surname><given-names>D. J.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Finding the missing heritability of complex diseases</article-title>. <source/>Nature
<volume>461</volume>, <fpage>747</fpage>–<lpage>753</lpage>. <pub-id pub-id-type="doi">10.1038/nature08494</pub-id>
<pub-id pub-id-type="pmid">19812666</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mark</surname><given-names>W.</given-names></name><name><surname>Toulopoulou</surname><given-names>T.</given-names></name></person-group> (<year>2016</year>). <article-title>Cognitive intermediate phenotype and genetic risk for psychosis</article-title>. <source/>Curr. Opin. Neurobiol.
<volume>36</volume>, <fpage>23</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2015.08.008</pub-id>
<pub-id pub-id-type="pmid">26363129</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marshall</surname><given-names>C. R.</given-names></name><name><surname>Howrigan</surname><given-names>D. P.</given-names></name><name><surname>Merico</surname><given-names>D.</given-names></name><name><surname>Thiruvahindrapuram</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Greer</surname><given-names>D. S.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects</article-title>. <source/>Nat. Genet.
<volume>49</volume>, <fpage>27</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3725</pub-id>
<pub-id pub-id-type="pmid">27869829</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCutcheon</surname><given-names>R. A.</given-names></name><name><surname>Abi-Dargham</surname><given-names>A.</given-names></name><name><surname>Howes</surname><given-names>O. D.</given-names></name></person-group> (<year>2019</year>). <article-title>Schizophrenia, dopamine and the striatum: from biology to symptoms</article-title>. <source/>Trends Neurosci.
<volume>42</volume>, <fpage>205</fpage>–<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1002/wps.20693</pub-id>
<pub-id pub-id-type="pmid">30621912</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meier</surname><given-names>M. H.</given-names></name><name><surname>Caspi</surname><given-names>A.</given-names></name><name><surname>Reichenberg</surname><given-names>A.</given-names></name><name><surname>Keefe</surname><given-names>R. S.</given-names></name><name><surname>Fisher</surname><given-names>H. L.</given-names></name><name><surname>Harrington</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study</article-title>. <source/>Am. J. Psychiatry
<volume>171</volume>, <fpage>91</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2013.12111438</pub-id>
<pub-id pub-id-type="pmid">24030246</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mullin</surname><given-names>A. P.</given-names></name><name><surname>Sadanandappa</surname><given-names>M. K.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Dickman</surname><given-names>D. K.</given-names></name><name><surname>VijayRaghavan</surname><given-names>K.</given-names></name><name><surname>Ramaswami</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Gene dosage in the dysbindin schizophrenia susceptibility network differentially affects synaptic function and plasticity</article-title>. <source/>J. Neurosci.
<volume>35</volume>, <fpage>325</fpage>–<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3542-14.2015</pub-id>
<pub-id pub-id-type="pmid">25568125</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nazarian</surname><given-names>R.</given-names></name><name><surname>Starcevic</surname><given-names>M.</given-names></name><name><surname>Spencer</surname><given-names>M. J.</given-names></name><name><surname>Dell’Angelica</surname><given-names>E. C.</given-names></name></person-group> (<year>2006</year>). <article-title>Reinvestigation of the dysbindin subunit of BLOC-1 (biogenesis of lysosome-related organelles complex-1) as a dystrobrevin-binding protein</article-title>. <source/>Biochem. J.
<volume>395</volume>, <fpage>587</fpage>–<lpage>598</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20051965</pub-id>
<pub-id pub-id-type="pmid">16448387</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Numakawa</surname><given-names>T.</given-names></name><name><surname>Yagasaki</surname><given-names>Y.</given-names></name><name><surname>Ishimoto</surname><given-names>T.</given-names></name><name><surname>Okada</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Iwata</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia</article-title>. <source/>Hum. Mol. Genet.
<volume>13</volume>, <fpage>2699</fpage>–<lpage>2708</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddh280</pub-id>
<pub-id pub-id-type="pmid">15345706</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O’Tuathaigh</surname><given-names>C. M.</given-names></name><name><surname>Waddington</surname><given-names>J. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Closing the translational gap between mutant mouse models and the clinical reality of psychotic illness</article-title>. <source/>Neurosci. Biobehav. Rev.
<volume>58</volume>, <fpage>19</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2015.01.016</pub-id>
<pub-id pub-id-type="pmid">25616181</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Owen</surname><given-names>M. J.</given-names></name><name><surname>Sawa</surname><given-names>A.</given-names></name><name><surname>Mortensen</surname><given-names>P. B.</given-names></name></person-group> (<year>2016</year>). <article-title>Schizophrenia</article-title>. <source/>Lancet
<volume>388</volume>, <fpage>86</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)01121-6</pub-id>
<pub-id pub-id-type="pmid">26777917</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oyama</surname><given-names>S.</given-names></name><name><surname>Yamakawa</surname><given-names>H.</given-names></name><name><surname>Sasagawa</surname><given-names>N.</given-names></name><name><surname>Hosoi</surname><given-names>Y.</given-names></name><name><surname>Futai</surname><given-names>E.</given-names></name><name><surname>Ishiura</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Dysbindin-1, a schizophrenia-related protein, functionally interacts with the DNA-dependent protein kinase complex in an isoform-dependent manner</article-title>. <source/>PloS One
<volume>4</volume>, <fpage>e4199</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0004199</pub-id>
<pub-id pub-id-type="pmid">19142223</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Papaleo</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Garcia</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Crawley</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors <italic>via</italic> dopamine/D2 pathways</article-title>. <source/>Mol. Psychiatry
<volume>7</volume>, <fpage>85</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2010.106</pub-id>
</mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Papaleo</surname><given-names>F.</given-names></name><name><surname>Burdick</surname><given-names>M. C.</given-names></name><name><surname>Callicott</surname><given-names>J. H.</given-names></name><name><surname>Weinberger</surname><given-names>D. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans</article-title>. <source/>Mol. Psychiatry
<volume>19</volume>, <fpage>311</fpage>–<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2013.133</pub-id>
<pub-id pub-id-type="pmid">24145376</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peters</surname><given-names>K.</given-names></name><name><surname>Wiltshire</surname><given-names>S.</given-names></name><name><surname>Henders</surname><given-names>A. K.</given-names></name><name><surname>Dragović</surname><given-names>M.</given-names></name><name><surname>Badcock</surname><given-names>J. C.</given-names></name><name><surname>Chandler</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Comprehensive analysis of tagging sequence variants in DTNBP1 shows no association with schizophrenia or with its composite neurocognitive endophenotypes</article-title>. <source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
<volume>147B</volume>, <fpage>1159</fpage>–<lpage>1166</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.30741</pub-id>
<pub-id pub-id-type="pmid">18314870</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petit</surname><given-names>E. I.</given-names></name><name><surname>Michalak</surname><given-names>Z.</given-names></name><name><surname>Cox</surname><given-names>R.</given-names></name><name><surname>O’Tuathaigh</surname><given-names>C. M.</given-names></name><name><surname>Clarke</surname><given-names>N.</given-names></name><name><surname>Tighe</surname><given-names>O.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Dysregulation of specialized delay/interference-dependent working memory following loss of dysbindin-1A in schizophrenia-related phenotypes</article-title>. <source/>Neuropsychopharmacology
<volume>42</volume>, <fpage>1349</fpage>–<lpage>1360</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2016.282</pub-id>
<pub-id pub-id-type="pmid">27986973</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rahmanzadeh</surname><given-names>R.</given-names></name><name><surname>Eftekhari</surname><given-names>S.</given-names></name><name><surname>Shahbazi</surname><given-names>A.</given-names></name><name><surname>Khodaei Ardakani</surname><given-names>M. R.</given-names></name><name><surname>Rahmanzade</surname><given-names>R.</given-names></name><name><surname>Mehrabi</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2017</year>a). <article-title>Effect of bumetanide, a selective NKCC1 inhibitor, on hallucinations of schizophrenic patients; a double-blind randomized clinical trial</article-title>. <source/>Schizophr. Res.
<volume>184</volume>, <fpage>145</fpage>–<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2016.12.002</pub-id>
<pub-id pub-id-type="pmid">27956008</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rahmanzadeh</surname><given-names>R.</given-names></name><name><surname>Shahbazi</surname><given-names>A.</given-names></name><name><surname>Ardakani</surname><given-names>M. K.</given-names></name><name><surname>Mehrabi</surname><given-names>S.</given-names></name><name><surname>Rahmanzade</surname><given-names>R.</given-names></name><name><surname>Joghataei</surname><given-names>M. T.</given-names></name></person-group> (<year>2017</year>b). <article-title>Lack of the effect of bumetanide, a selective NKCC1 inhibitor, in patients with schizophrenia: A double-blind randomized trial</article-title>. <source/>Psychiatry Clin. Neurosci.
<volume>71</volume>, <fpage>72</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1111/pcn.12475</pub-id>
<pub-id pub-id-type="pmid">27800670</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rammos</surname><given-names>A.</given-names></name><name><surname>Gonzalez</surname><given-names>L. A. N.</given-names></name><collab>Schizophrenia Working Group of the Psychiatric Genomics Consortium</collab><name><surname>Weinberger</surname><given-names>D. R.</given-names></name><name><surname>Mitchell</surname><given-names>K. J.</given-names></name><name><surname>Nicodemus</surname><given-names>K. K.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of polygenic risk score gene-set analysis in the context of the omnigenic model of schizophrenia</article-title>. <source/>Neuropsychopharmacology. <pub-id pub-id-type="doi">10.1038/s41386-019-0410-z</pub-id>
</mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Richards</surname><given-names>A. L.</given-names></name><name><surname>Pardiñas</surname><given-names>A. F.</given-names></name><name><surname>Frizzati</surname><given-names>A.</given-names></name><name><surname>Tansey</surname><given-names>K. E.</given-names></name><name><surname>Lynham</surname><given-names>A. J.</given-names></name><name><surname>Holmans</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>The relationship between polygenic risk scores and cognition in schizophrenia</article-title>. <source/>Schizophr. Bull., <fpage>pii: sbz061</fpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbz061</pub-id>
</mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saggu</surname><given-names>S.</given-names></name><name><surname>Cannon</surname><given-names>T. D.</given-names></name><name><surname>Jentsch</surname><given-names>J. D.</given-names></name><name><surname>Lavin</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>Potential molecular mechanisms for decreased synaptic glutamate release in dysbindin-1 mutant mice</article-title>. <source/>Schizophr. Res.
<volume>146</volume>, <fpage>254</fpage>–<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2013.01.037</pub-id>
<pub-id pub-id-type="pmid">23473812</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Savage</surname><given-names>J. E.</given-names></name><name><surname>Jansen</surname><given-names>P. R.</given-names></name><name><surname>Stringer</surname><given-names>S.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Bryois</surname><given-names>J.</given-names></name><name><surname>de Leeuw</surname><given-names>C. A.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence</article-title>. <source/>Nat. Genet.
<volume>50</volume>, <fpage>912</fpage>–<lpage>919</lpage>. <pub-id pub-id-type="doi">10.1038/s41588-018-0152-6</pub-id>
<pub-id pub-id-type="pmid">29942086</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schaefer</surname><given-names>J.</given-names></name><name><surname>Giangrande</surname><given-names>E.</given-names></name><name><surname>Weinberger</surname><given-names>D. R.</given-names></name><name><surname>Dickinson</surname><given-names>D.</given-names></name></person-group> (<year>2013</year>). <article-title>The global cognitive impairment in schizophrenia: consistent over decades and around the world</article-title>. <source/>Schizophr. Res.
<volume>150</volume>, <fpage>42</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2013.07.009</pub-id>
<pub-id pub-id-type="pmid">23911259</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scheggia</surname><given-names>D.</given-names></name><name><surname>Mastrogiacomo</surname><given-names>R.</given-names></name><name><surname>Mereu</surname><given-names>M.</given-names></name><name><surname>Sannino</surname><given-names>S.</given-names></name><name><surname>Straub</surname><given-names>R. E.</given-names></name><name><surname>Armando</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment</article-title>. <source/>Nat. Commun.
<volume>9</volume>, <fpage>2265</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-04711-w</pub-id>
<pub-id pub-id-type="pmid">29891954</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>Schizophrenia Working Group of the Psychiatric Genomics Consortium</collab></person-group> (<year>2014</year>). <article-title>Biological insights from 108 schizophrenia-associated genetic loci</article-title>. <source/>Nature
<volume>511</volume>, <fpage>421</fpage>–<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1038/nature13595</pub-id>
<pub-id pub-id-type="pmid">25056061</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shao</surname><given-names>L.</given-names></name><name><surname>Shuai</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Schizophrenia susceptibility gene dysbindin regulates glutamatergic and dopaminergic functions <italic>via</italic> distinctive mechanisms in Drosophila</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>108</volume>, <fpage>18831</fpage>–<lpage>18836</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1114569108</pub-id>
<pub-id pub-id-type="pmid">22049342</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shintani</surname><given-names>N.</given-names></name><name><surname>Onaka</surname><given-names>Y.</given-names></name><name><surname>Hashimoto</surname><given-names>R.</given-names></name><name><surname>Takamura</surname><given-names>H.</given-names></name><name><surname>Nagata</surname><given-names>T.</given-names></name><name><surname>Umeda-Yano</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Behavioral characterization of mice overexpressing human dysbindin-1</article-title>. <source/>Mol. Brain
<volume>7</volume>, <fpage>74</fpage>. <pub-id pub-id-type="doi">10.1186/s13041-014-0074-x</pub-id>
<pub-id pub-id-type="pmid">25298178</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sillitoe</surname><given-names>R. V.</given-names></name><name><surname>Benson</surname><given-names>M. A.</given-names></name><name><surname>Blake</surname><given-names>D. J.</given-names></name><name><surname>Hawkes</surname><given-names>R.</given-names></name></person-group> (<year>2003</year>). <article-title>Abnormal dysbindin expression in cerebellar mossy fiber synapses in the mdx mouse model of Duchenne muscular dystrophy</article-title>. <source/>J. Neurosci.
<volume>23</volume>, <fpage>6576</fpage>–<lpage>6585</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-16-06576.2003</pub-id>
<pub-id pub-id-type="pmid">12878699</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sinclair</surname><given-names>D.</given-names></name><name><surname>Cesare</surname><given-names>J.</given-names></name><name><surname>McMullen</surname><given-names>M.</given-names></name><name><surname>Carlson</surname><given-names>G. C.</given-names></name><name><surname>Hahn</surname><given-names>C. G.</given-names></name><name><surname>Borgmann-Winter</surname><given-names>K. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Effects of sex and DTNBP1 (dysbindin) null gene mutation on the developmental GluN2B-GluN2A switch in the mouse cortex and hippocampus</article-title>. <source/>J. Neurodev. Disord.
<volume>8</volume>, <fpage>14</fpage>. <pub-id pub-id-type="doi">10.1186/s11689-016-9148-7</pub-id>
<pub-id pub-id-type="pmid">27134685</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spiegel</surname><given-names>S.</given-names></name><name><surname>Chiu</surname><given-names>A.</given-names></name><name><surname>James</surname><given-names>A. S.</given-names></name><name><surname>Jentsch</surname><given-names>J. D.</given-names></name><name><surname>Karlsgodt</surname><given-names>K. H.</given-names></name></person-group> (<year>2015</year>). <article-title>Recognition deficits in mice carrying mutations of genes encoding BLOC-1 subunits pallidin or dysbindin</article-title>. <source/>Genes Brain Behav.
<volume>14</volume>, <fpage>618</fpage>–<lpage>624</lpage>. <pub-id pub-id-type="doi">10.1111/gbb.12240</pub-id>
<pub-id pub-id-type="pmid">26294018</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Starcevic</surname><given-names>M.</given-names></name><name><surname>Dell’Angelica</surname><given-names>E. C.</given-names></name></person-group> (<year>2004</year>). <article-title>Identification of snapin and three novel proteins (BLOS1, BLOS2, and BLOS3/reduced pigmentation) as subunits of biogenesis of lysosome-related organelles complex-1 (BLOC-1)</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <page-range>28393–401</page-range>.</mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Straub</surname><given-names>R. E.</given-names></name><name><surname>MacLean</surname><given-names>C. J.</given-names></name><name><surname>O’Neill</surname><given-names>F. A.</given-names></name><name><surname>Burke</surname><given-names>J.</given-names></name><name><surname>Murphy</surname><given-names>B.</given-names></name><name><surname>Duke</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>1995</year>). <article-title>A potential vulnerability locus for schizophrenia on chromosome 6p24–22: evidence for genetic heterogeneity</article-title>. <source/>Nat. Genet.
<volume>11</volume>, <fpage>287</fpage>–<lpage>293</lpage>. <pub-id pub-id-type="doi">10.1038/ng1195-287</pub-id>
<pub-id pub-id-type="pmid">7581452</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Strohmaier</surname><given-names>J.</given-names></name><name><surname>Frank</surname><given-names>J.</given-names></name><name><surname>Wendland</surname><given-names>J. R.</given-names></name><name><surname>Schumacher</surname><given-names>J.</given-names></name><name><surname>Jamra</surname><given-names>R. A.</given-names></name><name><surname>Treutlein</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>A reappraisal of the association between Dysbindin (DTNBP1) and schizophrenia in a large combined case-control and family-based sample of German ancestry</article-title>. <source/>Schizophr. Res.
<volume>118</volume>, <fpage>98</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2009.12.025</pub-id>
<pub-id pub-id-type="pmid">20083391</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>C. R.</given-names></name><name><surname>Funk</surname><given-names>A. J.</given-names></name><name><surname>Shan</surname><given-names>D.</given-names></name><name><surname>Haroutunian</surname><given-names>V.</given-names></name><name><surname>McCullumsmith</surname><given-names>R. E.</given-names></name></person-group> (<year>2015</year>). <article-title>Decreased chloride channel expression in the dorsolateral prefrontal cortex in schizophrenia</article-title>. <source/>PloS One
<volume>10</volume>, <fpage>e0123158</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0123158</pub-id>
<pub-id pub-id-type="pmid">25826365</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Straub</surname><given-names>R. E.</given-names></name><name><surname>Mayhew</surname><given-names>M. B.</given-names></name><name><surname>Vakkalanka</surname><given-names>R. K.</given-names></name><name><surname>Kolachana</surname><given-names>B.</given-names></name><name><surname>Goldberg</surname><given-names>T. E.</given-names></name><name><surname>Egan</surname><given-names>M. F.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>MUTED, a protein that binds to dysbindin (DTNBP1), is associated with schizophrenia</article-title>. <source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
<volume>138B</volume>, <fpage>136</fpage>.</mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Swank</surname><given-names>R. T.</given-names></name><name><surname>Sweet</surname><given-names>H. O.</given-names></name><name><surname>Davisson</surname><given-names>M. T.</given-names></name><name><surname>Reddington</surname><given-names>M.</given-names></name><name><surname>Novak</surname><given-names>E. K.</given-names></name></person-group> (<year>1991</year>). <article-title>Sandy: a new mouse model for platelet storage pool deficiency</article-title>. <source/>Genet. Res.
<volume>58</volume>, <fpage>51</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1017/s0016672300029608</pub-id>
<pub-id pub-id-type="pmid">1936982</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takao</surname><given-names>K.</given-names></name><name><surname>Toyama</surname><given-names>K.</given-names></name><name><surname>Nakanishi</surname><given-names>K.</given-names></name><name><surname>Hattori</surname><given-names>S.</given-names></name><name><surname>Takamura</surname><given-names>H.</given-names></name><name><surname>Takeda</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Impaired long-term memory retention and working memory in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia</article-title>. <source/>Mol. Brain
<volume>1</volume>, <fpage>11</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1186/1756-6606-1-11</pub-id>
<pub-id pub-id-type="pmid">18945333</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Eidem</surname><given-names>W. L.</given-names></name><name><surname>Tinsley</surname><given-names>C. L.</given-names></name><name><surname>Benson</surname><given-names>M. A.</given-names></name><name><surname>Thompson</surname><given-names>E. W.</given-names></name><name><surname>Smith</surname><given-names>R. J.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia</article-title>. <source/>J. Clin. Invest.
<volume>113</volume>, <fpage>1353</fpage>–<lpage>1363</lpage>. <pub-id pub-id-type="doi">10.1172/JCI20425</pub-id>
<pub-id pub-id-type="pmid">15124027</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Cho</surname><given-names>D.-S.</given-names></name><name><surname>Ong</surname><given-names>W.-Y.</given-names></name><name><surname>Benson</surname><given-names>M. A.</given-names></name><name><surname>Han</surname><given-names>L.-Y.</given-names></name><name><surname>Kazi</surname><given-names>H. A.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin</article-title>. <source/>Hum. Mol. Genet.
<volume>15</volume>, <fpage>3041</fpage>–<lpage>3054</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddl246</pub-id>
<pub-id pub-id-type="pmid">16980328</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talbot</surname><given-names>K.</given-names></name><name><surname>Louneva</surname><given-names>N.</given-names></name><name><surname>Cohen</surname><given-names>J. W.</given-names></name><name><surname>Kazi</surname><given-names>H.</given-names></name><name><surname>Blake</surname><given-names>D. J.</given-names></name><name><surname>Arnold</surname><given-names>S. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Synaptic dysbindin-1 reductions in schizophrenia occur in an isoform-specific manner indicating their subsynaptic location</article-title>. <source/>PloS One
<volume>6</volume>, <fpage>e16886</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0016886</pub-id>
<pub-id pub-id-type="pmid">21390302</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Talbot</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research</article-title>. <source/>Prog.Brain Res.
<volume>179</volume>, <fpage>87</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/S0079-6123(09)17910-4</pub-id>
<pub-id pub-id-type="pmid">20302821</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tam</surname><given-names>V.</given-names></name><name><surname>Patel</surname><given-names>N.</given-names></name><name><surname>Turcotte</surname><given-names>M.</given-names></name><name><surname>Bossé</surname><given-names>Y.</given-names></name><name><surname>Paré</surname><given-names>G.</given-names></name><name><surname>Meyre</surname><given-names>D.</given-names></name></person-group> (<year>2019</year>). <article-title>Benefits and limitations of genome-wide association studies</article-title>. <source/>Nat. Rev. Genet.
<volume>20</volume>, <fpage>467</fpage>–<lpage>484</lpage>. <pub-id pub-id-type="doi">10.1038/s41576-019-0127-1</pub-id>
<pub-id pub-id-type="pmid">31068683</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tamminga</surname><given-names>C. A.</given-names></name><name><surname>Stan</surname><given-names>A. D.</given-names></name><name><surname>Wagner</surname><given-names>A. D.</given-names></name></person-group> (<year>2010</year>). <article-title>The hippocampal formation in schizophrenia</article-title>. <source/>Am. J. Psychiatry
<volume>167</volume>, <fpage>1178</fpage>–<lpage>1193</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2010.09081187</pub-id>
<pub-id pub-id-type="pmid">20810471</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taneichi-Kuroda</surname><given-names>S.</given-names></name><name><surname>Taya</surname><given-names>S.</given-names></name><name><surname>Hikita</surname><given-names>T.</given-names></name><name><surname>Fujino</surname><given-names>Y.</given-names></name><name><surname>Kaibuchi</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>Direct interaction of Dysbindin with the AP-3 complex <italic>via</italic> its mu subunit</article-title>. <source/>Neurochem. Int.
<volume>54</volume>, <fpage>431</fpage>–<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2009.01.014</pub-id>
<pub-id pub-id-type="pmid">19428785</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>LeGros</surname><given-names>R. P.</given-names></name><name><surname>Louneva</surname><given-names>N.</given-names></name><name><surname>Yeh</surname><given-names>L.</given-names></name><name><surname>Cohen</surname><given-names>J. W.</given-names></name><name><surname>Hahn</surname><given-names>C.-G.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression</article-title>. <source/>Hum. Mol. Genet.
<volume>18</volume>, <fpage>3851</fpage>–<lpage>3863</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddp329</pub-id>
<pub-id pub-id-type="pmid">19617633</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tansey</surname><given-names>K. E.</given-names></name><name><surname>Rees</surname><given-names>E.</given-names></name><name><surname>Linden</surname><given-names>D. E.</given-names></name><name><surname>Ripke</surname><given-names>S.</given-names></name><name><surname>Chambert</surname><given-names>K. D.</given-names></name><name><surname>Moran</surname><given-names>J. L.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Common alleles contribute to schizophrenia in CNV carriers</article-title>. <source/>Mol. Psychiatry
<volume>21</volume>, <fpage>1153</fpage>. <pub-id pub-id-type="doi">10.1038/mp.2015.170</pub-id>
</mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toulopoulou</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Cherny</surname><given-names>S.</given-names></name><name><surname>Dickinson</surname><given-names>D.</given-names></name><name><surname>Berman</surname><given-names>K. F.</given-names></name><name><surname>Straub</surname><given-names>R. E.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Polygenic risk score increases schizophrenia liability through cognition-relevant pathways</article-title>. <source/>Brain
<volume>142</volume>, <fpage>471</fpage>–<lpage>485</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awy279</pub-id>
<pub-id pub-id-type="pmid">30535067</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varela-Gomez</surname><given-names>N.</given-names></name><name><surname>Mata</surname><given-names>I.</given-names></name><name><surname>Perez-Iglesias</surname><given-names>R.</given-names></name><name><surname>Rodriguez-Sanchez</surname><given-names>J. M.</given-names></name><name><surname>Ayesa</surname><given-names>R.</given-names></name><name><surname>Fatjo-Vilas</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Dysbindin gene variability is associated with cognitive abnormalities in first-episode non-affective psychosis</article-title>. <source/>Cogn. Neuropsychiatry
<volume>20</volume>, <page-range>144–56</page-range>. <pub-id pub-id-type="doi">10.1080/13546805.2014.991780</pub-id>
</mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vijayraghavan</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Birnbaum</surname><given-names>S. G.</given-names></name><name><surname>Williams</surname><given-names>G. V.</given-names></name><name><surname>Arnsten</surname><given-names>A. F.</given-names></name></person-group> (<year>2007</year>). <article-title>Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory</article-title>. <source/>Nat. Neurosci.
<volume>10</volume>, <fpage>376</fpage>–<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1038/nn1846</pub-id>
<pub-id pub-id-type="pmid">17277774</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Waddington</surname><given-names>J. L.</given-names></name><name><surname>Hennessy</surname><given-names>R. J.</given-names></name><name><surname>O’Tuathaigh</surname><given-names>C. M. P.</given-names></name><name><surname>Owoeye</surname><given-names>O.</given-names></name><name><surname>Russell</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>). <article-title>Schizophrenia and the lifetime trajectory of psychotic illness: developmental neuroscience and pathobiology, redux</article-title>, in <source/>The origins of schizophrenia. Eds. <person-group person-group-type="editor"><name><surname>Brown</surname><given-names>A. S.</given-names></name><name><surname>Patterson</surname><given-names>P. H.</given-names></name></person-group> (<publisher-loc>New York</publisher-loc>: <publisher-name>Columbia University Press</publisher-name>), pp. <fpage>3</fpage>–<lpage>21</lpage>.</mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Lazarovici</surname><given-names>P.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name></person-group> (<year>2017</year>). <article-title>Dysbindin-1 involvement in the etiology of schizophrenia</article-title>. <source/>Int. J. Mol. Sci.
<volume>18</volume>, <fpage>pii: E2044</fpage>. <pub-id pub-id-type="doi">10.3390/ijms18102044</pub-id>
</mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Cao</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Waddington</surname><given-names>J. L.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>D2 receptor-mediated miRNA-143 expression is associated with the effects of antipsychotic drugs on phencyclidine-induced schizophrenia-related locomotor hyperactivity and with neuregulin-1 expression in mice</article-title>. <source/>Neuropharmacology. <volume>157</volume>, <fpage>107675</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.107675</pub-id>
<pub-id pub-id-type="pmid">31233824</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weickert</surname><given-names>C. S.</given-names></name><name><surname>Straub</surname><given-names>R. E.</given-names></name><name><surname>McClintock</surname><given-names>B. W.</given-names></name><name><surname>Matsumoto</surname><given-names>M.</given-names></name><name><surname>Hashimoto</surname><given-names>R.</given-names></name><name><surname>Hyde</surname><given-names>T. M.</given-names></name><etal></etal></person-group> (<year>2004</year>). <article-title>Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain</article-title>. <source/>Arch. Gen. Psychiatry
<volume>61</volume>, <fpage>544</fpage>–<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.61.6.544</pub-id>
<pub-id pub-id-type="pmid">15184234</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weickert</surname><given-names>C. S.</given-names></name><name><surname>Rothmond</surname><given-names>D. A.</given-names></name><name><surname>Hyde</surname><given-names>T. M.</given-names></name><name><surname>Kleinman</surname><given-names>J. E.</given-names></name><name><surname>Straub</surname><given-names>R. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients</article-title>. <source/>Schizophr. Res.
<volume>98</volume>, <fpage>105</fpage>–<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2007.05.041</pub-id>
<pub-id pub-id-type="pmid">17961984</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weinberger</surname><given-names>D. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Future of days past: neurodevelopment and schizophrenia</article-title>. <source/>Schizophr. Bull.
<volume>43</volume>, <fpage>1164</fpage>–<lpage>1168</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbx118</pub-id>
<pub-id pub-id-type="pmid">29040792</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weinberger</surname><given-names>D. R.</given-names></name></person-group> (<year>2019</year>). <article-title>Thinking about schizophrenia in an era of genomic medicine</article-title>. <source/>Am. J. Psychiatry
<volume>176</volume>, <fpage>12</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2018.18111275</pub-id>
<pub-id pub-id-type="pmid">30848926</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xavier</surname><given-names>R. M.</given-names></name><name><surname>Dungan</surname><given-names>J. R.</given-names></name><name><surname>Keefe</surname><given-names>R. S. E.</given-names></name><name><surname>Vorderstrasse</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Polygenic signal for symptom dimensions and cognitive performance in patients with chronic schizophrenia</article-title>. <source/>Schizophr. Res. Cogn.
<volume>12</volume>, <fpage>11</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.scog.2018.01.001</pub-id>
<pub-id pub-id-type="pmid">29552508</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Ye</surname><given-names>H.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Increased dysbindin-1B isoform expression in schizophrenia and its propensity in aggresome formation</article-title>. <source/>Cell. Discovery
<volume>1</volume>, <fpage>15032</fpage>. <pub-id pub-id-type="doi">10.1038/celldisc.2015.32</pub-id>
<pub-id pub-id-type="pmid">27462430</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name></person-group> (<year>2017</year>). <article-title>Hippocampal apoptosis and cognitive function in Dysbindin-1B mice</article-title>. <source/>Zhongguo Yi Xue Ke Xue Yuan Xue Bao.
<volume>39</volume>, <fpage>307</fpage>–<lpage>311</lpage>. <pub-id pub-id-type="doi">10.3881/j.issn.1000-503X.2017.03.002</pub-id>
<pub-id pub-id-type="pmid">28695798</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name></person-group> (<year>2016</year>). <article-title>The pathogenic mechanism of dysbindin-1B toxic aggregation: BLOC-1 and intercellular vesicle trafficking</article-title>. <source/>Neuroscience
<volume>333</volume>, <fpage>78</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.07.008</pub-id>
<pub-id pub-id-type="pmid">27421225</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Hei</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia</article-title>. <source/>Psychiatry Res.
<volume>273</volume>, <fpage>528</fpage>–<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2019.01.051</pub-id>
<pub-id pub-id-type="pmid">30710808</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. P.</given-names></name><name><surname>Burdick</surname><given-names>K. E.</given-names></name><name><surname>Lencz</surname><given-names>T.</given-names></name><name><surname>Malhotra</surname><given-names>A. K.</given-names></name></person-group> (<year>2010</year>). <article-title>Meta-analysis of genetic variation in DTNBP1 and general cognitive ability</article-title>. <source/>Biol. Psychiatry
<volume>68</volume>, <fpage>1126</fpage>–<lpage>1133</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2010.09.016</pub-id>
<pub-id pub-id-type="pmid">21130223</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zeng</surname><given-names>Z.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Little</surname><given-names>P. J.</given-names></name><name><surname>Srivastava</surname><given-names>L. K.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>The possible role of the Akt signaling pathway in schizophrenia</article-title>. <source/>Brain Res.
<volume>1470</volume>, <fpage>145</fpage>–<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2012.06.032</pub-id>
<pub-id pub-id-type="pmid">22771711</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>